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INFORMATION AVAILABLE ON-LINE 
 
 
All CDC NARMS Annual Reports and additional information about NARMS are posted on the CDC NARMS 
website: http://www.cdc.gov/narms. 
 
Additional general information about the NARMS surveillance program is posted on the Food and Drug 
Administration’s Center for Veterinary Medicine website: http://www.fda.gov/cvm/narms_pg.html. 
 
Information about animal isolates in NARMS is available on the U.S. Department of Agriculture–-Agricultural 
Research Service website: http://www.ars-grin.gov/ars/SoAtlantic/Athens/arru/narms.html. 
 
General information about antimicrobial resistance is posted on the CDC website: 
http://www.cdc.gov/drugresistance. 
 
Information regarding CDC’s Get Smart program is available at 
http://www.cdc.gov/drugresistance/community. 
 
General information about CDC’s Foodborne Diseases Active Surveillance Network (FoodNet) is available at 
http://www.cdc.gov/foodnet. 
 
General information about the National Molecular Subtyping Network for Foodborne Disease Surveillance 
(PulseNet) is available at http://www.cdc.gov/pulsenet. 
 
General information about the World Health Organization Global Salm-Surv is available at 
http://www.who.int/salmsurv/en. 
 
CDC Salmonella Annual Summaries are posted on the PHLIS website: 
http://www.cdc.gov/ncidod/dbmd/phlisdata/salmonella.htm. 
 
CDC Shigella Annual Summaries also posted on the PHLIS website: 
http://www.cdc.gov/ncidod/dbmd/phlisdata/shigella.htm. 
 








The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among 
the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and U.S. 
Department of Agriculture (USDA).  The primary purpose of NARMS at CDC is to monitor antimicrobial resistance 
among foodborne enteric bacteria isolated from humans.  Other components of the interagency NARMS program 
include surveillance for resistance in human enteric bacterial pathogens isolated from foods, conducted by the 
FDA Center for Veterinary Medicine (http://www.fda.gov/cvm/narms_pg.html), and resistance in human enteric 
pathogens isolated from animals, conducted by the USDA Agricultural Research Services (http://www.ars-
grin.gov/ars/SoAtlantic/Athens/arru/narms.html).  
 
Many NARMS activities are conducted within the framework of CDC’s Emerging Infections Program (EIP), 
Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network 
(FoodNet).  In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also 
includes public health research into the mechanisms of resistance, education efforts to promote prudent use of 
antimicrobial agents, and studies of resistance in commensal organisms. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among human non-Typhi Salmonella and 
Escherichia coli O157 isolates in 14 sites. In 1997, testing of human Campylobacter isolates was initiated in the 
five sites participating in FoodNet. Testing of human Salmonella Typhi and Shigella isolates was added in 1999. 
Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, Salmonella 
Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states 
have been participating in Campylobacter surveillance. 
 
This annual report includes CDC’s human surveillance data for 2004 for non-Typhi Salmonella, Salmonella Typhi, 
Shigella, and E. coli O157. Resistance trends and comparisons to previous years are included when appropriate. 
Antimicrobial subclasses defined by the Clinical and Laboratory Standards Institute (CLSI) are used in data 
presentation and analysis. CLSI subclasses constitute major classifications of antimicrobial agents, e.g., 
aminoglycosides and cephalosporins. 
 
This report also includes a section on the Enterococci Resistance Study, which is part of NARMS surveillance on 
commensal bacteria. Data from the 2004 Enterococci Resistance Study are presented, as are 2001–2003 data 
when reference to previous years is appropriate. In addition, Appendix A summarizes the Escherichia coli 
Resistance Surveillance Pilot Study conducted in 2004. 
 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.gov/narms.
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In 2004, all 50 states participated in NARMS, representing approximately 294 million persons (Table I). 
Surveillance for antimicrobial resistance included non-Typhi Salmonella, Salmonella Typhi, Shigella, and 
Escherichia coli O157. Campylobacter resistance to antimicrobial agents was monitored in 10 states that also 
participated in the Foodborne Diseases Active Surveillance Network (FoodNet), representing approximately 45 
million persons (15% of the U.S. population). 
 
 
CLINICALLY IMPORTANT RESISTANCE 
 
In the United States, certain quinolones (e.g., the fluoroquinolone ciprofloxacin) and third-generation 
cephalosporins (e.g., ceftriaxone) are antimicrobial agents commonly used to treat severe Campylobacter and 
Salmonella infections, including Salmonella serotype Typhi, the organism that causes Typhoid fever. Nalidixic 
acid is an elementary quinolone; resistance to nalidixic acid correlates with decreased susceptibility to 
ciprofloxacin and possible treatment failure. Ceftiofur is a third-generation cephalosporin used in food animals in 
the United States; resistance to ceftiofur correlates with decreased susceptibility to ceftriaxone. A substantial 
proportion of isolates tested by NARMS in 2004 demonstrated resistance to these clinically important 
antimicrobial agents, as follows: 
• 19.0% (66/347) of Campylobacter isolates were resistant to the fluoroquinolone ciprofloxacin, compared with 
12.9% (28/217) in 1997 (OR=1.6, 95% CI [1.0, 2.6]) (Table II). 
o 30.8% (8/26) of Campylobacter coli isolates were resistant to ciprofloxacin. 
o 18.1% (58/320) of Campylobacter jejuni isolates were resistant to ciprofloxacin. 
• 2.6% (47/1793) of non-Typhi Salmonella isolates were resistant to the quinolone nalidixic acid, compared with 
0.4% (5/1324) in 1996 (OR=9.2, 95% CI [3.6, 23.8]) (Table II). 
o Salmonella Enteritidis was the most common serotype among nalidixic acid-resistant non-Typhi 
Salmonella isolates: 38.3% (18/47) of quinolone-resistant isolates were serotype Enteritidis. 
o Nalidixic acid resistance in Salmonella Enteritidis was 6.6% (18/271) in 2004, compared with 
0.9% (3/351) in 1996 (OR 95% CI [2.3, 49.3]) (Table II). 
• 3.4% (61/1793) of non-Typhi Salmonella isolates were resistant to the third-generation cephalosporin 
ceftiofur, compared with 0.2% (2/1324) in 1996 (OR=34.5, 95% CI [8.3, 142.7]) (Table II). 
o Salmonella Newport was the most common serotype among ceftiofur-resistant non-Typhi 
Salmonella isolates: 47.5% (29/61) of ceftiofur-resistant isolates were serotype Newport. 
• 41.8% (127/304) of Salmonella Typhi isolates were resistant to the quinolone nalidixic acid, compared with 





• Multidrug resistance is described in NARMS by the number of antimicrobial subclasses or specific coresistant 
phenotypes. Antimicrobial subclasses are used as defined by the CLSI (Table III). For non-Typhi Salmonella, 
the most common multidrug-resistant phenotypes in 2004 were as follows: resistance to at least ampicillin, 
chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline (R-Type ACSSuT) and 
resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, 
amoxicillin-clavulanic acid, and ceftiofur, and decreased susceptibility to ceftriaxone (minimum inhibitory 
concentration ≥2 μg/mL) (MDR-AmpC). 
 
• 15.0% (269/1793) of non-Typhi Salmonella isolates were resistant to two or more CLSI subclasses, and 8.1% 
(146/1793) were resistant to five or more CLSI subclasses. 
o 17.4% (33/190) of Salmonella Newport isolates were resistant to two or more CLSI subclasses, 
and 14.7% (28/190) were resistant to five or more CLSI subclasses. 
o 37.2% (142/382) of Salmonella Typhimurium isolates were resistant to two or more CLSI 
subclasses, and 24.3% (93/382) were resistant to five or more CLSI subclasses. 
o 3.0% (8/271) of Salmonella Enteritidis isolates were resistant to two or more CLSI subclasses, 
and 0.7% (2/271) were resistant to five or more CLSI subclasses. 
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• 7.1% (128/1793) of non-Typhi Salmonella isolates had R-Type ACSSuT, compared with 8.8% (116/1324) in 
1996 (Table 1.3). 
o 23.3% (89/382) of Salmonella Typhimurium isolates were R-Type ACSSuT, compared with 
33.7% (103/306) in 1996 (OR=0.6, 95% CI [0.4, 0.8]) (Table II). 
o 14.7% (28/190) of Salmonella Newport isolates were R-Type ACSSuT, compared with 5.9% 
(3/51) in 1996. 
• 2.3% (42/1793) of non-Typhi Salmonella isolates had the MDR-AmpC phenotype. These isolates consisted of 
five different serotypes. In 1996, MDR-AmpC resistance was not detected in any serotype. 
o 14.7% (28/189) of Salmonella Newport isolates were at least MDR-AmpC resistant, compared 
with none (0/51) in 1996 (95% CI [3.4, infinity]) (Table II). 
o 2.6% (10/382) of Salmonella Typhimurium isolates were at least MDR-AmpC resistant.
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N (%) N (%) N (%) N (%) N (%)
Alabama 4,530,182 36 (2.0%) 1 (0.3%) 9 (2.8%) 1 (0.6%) N/A
Alaska 655,435 2 (0.1%) 0 (0.0%) 1 (0.3%) 1 (0.6%) N/A
Arizona 5,743,834 28 (1.6%) 2 (0.7%) 8 (2.5%) 0 (0.0%) N/A
Arkansas 2,752,629 22 (1.2%) 0 (0.0%) 4 (1.3%) 3 (1.8%) N/A
California‡ 32,056,400 109 (6.1%) 65 (21.4%) 1 (0.3%) 7 (4.1%) 27 (7.8%)
Colorado 4,601,403 23 (1.3%) 4 (1.3%) 6 (1.9%) 2 (1.2%) 33 (9.5%)
Connecticut 3,503,604 26 (1.5%) 9 (3.0%) 4 (1.3%) 5 (3.0%) 40 (11.5%)
Delaware 830,364 8 (0.4%) 1 (0.3%) 0 (0.0%) 0 (0.0%) N/A
District of Columbia 553,523 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) N/A
Florida 17,397,161 54 (3.0%) 10 (3.3%) 0 (0.0%) 0 (0.0%) N/A
Georgia 8,829,383 111 (6.2%) 3 (1.0%) 24 (7.6%) 20 (11.8%) 45 (13.0%)
Hawaii 1,262,840 18 (1.0%) 7 (2.3%) 3 (0.9%) 0 (0.0%) N/A
Houston, Texas§ 2,011,119 33 (1.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) N/A
Idaho 1,393,262 9 (0.5%) 0 (0.0%) 1 (0.3%) 3 (1.8%) N/A
Illinois 12,713,634 74 (4.1%) 14 (4.6%) 19 (6.0%) 5 (3.0%) N/A
Indiana 6,237,569 35 (2.0%) 1 (0.3%) 2 (0.6%) 2 (1.2%) N/A
Iowa 2,954,451 14 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) N/A
Kansas 2,735,502 16 (0.9%) 0 (0.0%) 3 (0.9%) 1 (0.6%) N/A
Kentucky 4,145,922 20 (1.1%) 3 (1.0%) 4 (1.3%) 0 (0.0%) N/A
Los Angeles¶ 3,837,399 60 (3.3%) 22 (7.2%) 7 (2.2%) 0 (0.0%) N/A
Louisiana 4,515,770 46 (2.6%) 0 (0.0%) 4 (1.3%) 0 (0.0%) N/A
Maine 1,317,253 5 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.6%) N/A
Maryland 5,558,058 44 (2.5%) 16 (5.3%) 8 (2.5%) 3 (1.8%) 22 (6.3%)
Massachusetts 6,416,505 58 (3.2%) 16 (5.3%) 8 (2.5%) 4 (2.4%) N/A
Michigan 10,112,620 40 (2.2%) 9 (3.0%) 7 (2.2%) 4 (2.4%) N/A
Minnesota 5,100,958 33 (1.8%) 6 (2.0%) 2 (0.6%) 5 (3.0%) 53 (15.3%)
Mississippi 2,902,966 43 (2.4%) 0 (0.0%) 1 (0.3%) 0 (0.0%) N/A
Missouri 5,754,618 43 (2.4%) 1 (0.3%) 9 (2.8%) 6 (3.6%) N/A
Montana 926,865 5 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.6%) N/A
Nebraska 1,747,214 12 (0.7%) 2 (0.7%) 8 (2.5%) 5 (3.0%) N/A
Nevada 2,334,771 12 (0.7%) 2 (0.7%) 4 (1.3%) 2 (1.2%) N/A
New Hampshire 1,299,500 8 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.6%) N/A
New Jersey 8,698,879 44 (2.5%) 17 (5.6%) 9 (2.8%) 10 (5.9%) N/A
New Mexico 1,903,289 19 (1.1%) 0 (0.0%) 8 (2.5%) 0 (0.0%) 21 (6.1%)
New York4 11,062,382 66 (3.7%) 10 (3.3%) 14 (4.4%) 9 (5.3%) 50 (14.4%)
New York City** 8,164,706 56 (3.1%) 29 (9.5%) 6 (1.9%) 3 (1.8%) N/A
North Carolina 8,541,221 86 (4.8%) 4 (1.3%) 7 (2.2%) 8 (4.7%) N/A
North Dakota 634,366 3 (0.2%) 0 (0.0%) 1 (0.3%) 1 (0.6%) N/A
Ohio 11,459,011 58 (3.2%) 5 (1.6%) 5 (1.6%) 5 (3.0%) N/A
Oklahoma 3,523,553 20 (1.1%) 0 (0.0%) 26 (8.2%) 4 (2.4%) N/A
Oregon 3,594,586 19 (1.1%) 1 (0.3%) 4 (1.3%) 3 (1.8%) 29 (8.4%)
Pennsylvania 12,406,292 80 (4.5%) 8 (2.6%) 6 (1.9%) 10 (5.9%) N/A
Rhode Island 1,080,632 9 (0.5%) 2 (0.7%) 0 (0.0%) 1 (0.6%) N/A
South Carolina 4,198,068 3 (0.2%) 0 (0.0%) 3 (0.9%) 0 (0.0%) N/A
South Dakota 770,883 10 (0.6%) 0 (0.0%) 6 (1.9%) 9 (5.3%) N/A
Tennessee 5,900,962 38 (2.1%) 4 (1.3%) 23 (7.3%) 2 (1.2%) 27 (7.8%)
Texas†† 20,478,903 48 (2.7%) 11 (3.6%) 22 (7.0%) 1 (0.6%) N/A
Utah 2,389,039 12 (0.7%) 1 (0.3%) 1 (0.3%) 3 (1.8%) N/A
Vermont 621,394 2 (0.1%) 1 (0.3%) 1 (0.3%) 0 (0.0%) N/A
Virginia 7,459,827 57 (3.2%) 7 (2.3%) 4 (1.3%) 1 (0.6%) N/A
Washington 6,203,788 38 (2.1%) 6 (2.0%) 6 (1.9%) 8 (4.7%) N/A
West Virginia 1,815,354 30 (1.7%) 0 (0.0%) 1 (0.3%) 1 (0.6%) N/A
Wisconsin 5,509,026 43 (2.4%) 3 (1.0%) 13 (4.1%) 5 (3.0%) N/A
Wyoming 506,529 5 (0.3%) 0 (0.0%) 1 (0.3%) 3 (1.8%) N/A
Total 293,655,404 1793 (100.0%) 304 (100.0%) 316 (100.0%) 169 (100.0%) 347 (100.0%)
* US Census Bureau, 2004
† Campylobacter  isolates were submitted only from FoodNet sites; total population size of FoodNet sites was 44,531,182
‡ Excluding Los Angeles County
§ Houston City
¶ Los Angeles County
4 Excluding New York City
** Five burroughs of New York City (Bronx, Brooklyn, Manhattan, Queens, Staten Island)
†† Excluding Houston, Texas
Shigella E. coli  O157 Campylobacter†









Table II: Summary of trend analysis of the proportion of specific resistance phenotypes among 
Campylobacter, non-Typhi Salmonella, and Salmonella Typhi isolates, 2004 
 
Resistance Phenotype Reference Year Odds Ratio* 95% CI* 
Ciprofloxacin resistance in Campylobacter 1997 1.6 1.0–2.6 
Nalidixic acid resistance in non-Typhi 
Salmonella 1996 9.2 3.6–23.8 
Nalidixic acid resistance in Salmonella 
Enteritidis 1996 –
† 2.3–49.3†
Ceftiofur resistance in non-Typhi 
Salmonella 1996 34.5 8.3–142.7 
Nalidixic acid resistance in Salmonella 
Typhi 1999 3.1 1.9–4.9 
ACSSuT resistance in Salmonella 
Typhimurium‡ 1996 0.6 0.4–0.8 




* For logistic regression models that adjusted for site, odds ratios (ORs) (2004 vs. reference year) and 95% confidence 
intervals (CIs) were calculated using unconditional maximum likelihood estimation. 
† Model included only year. In the analysis, the maximum likelihood estimate of the OR did not exist; only the 95% CIs, 
calculated using unconditional exact methods, are reported. 
‡ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline. 
§ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-
clavulanic acid, and ceftiofur, and decreased susceptibility to ceftriaxone (minimum inhibitory concentration ≥2 μg/mL). 
 
 12
SURVEILLANCE AND LABORATORY TESTING METHODS 
 
 
SURVEILLANCE SITES AND ISOLATE SUBMISSION 
 
In 2004, NARMS conducted nationwide surveillance among the population of approximately 294 million persons 
(2004 U.S. Census Bureau estimates). Public health laboratories systematically selected every 20th non-Typhi 
Salmonella (i.e., all Salmonella serotypes except serotype Typhi), Shigella, and Escherichia coli O157 isolate and 
every Salmonella Typhi isolate received at their laboratories and forwarded these isolates to CDC for 
antimicrobial susceptibility testing. 
 
Public health laboratories of the 10 state health departments that participated in CDC’s Foodborne Diseases 
Active Surveillance Network (FoodNet) during 2004 forwarded Campylobacter isolates to CDC for susceptibility 
testing. The FoodNet sites, representing approximately 45 million persons (2004 U.S. Census Bureau estimates), 
comprised California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, 
and Tennessee. Campylobacter isolates submitted to NARMS were selected in one of several ways. In Maryland, 
Minnesota, New Mexico, New York, and Tennessee, one isolate a week was selected (usually the first isolate 
received each week was selected, but otherwise isolates were randomly selected) from the collection of isolates 
sent to the state health department laboratory from almost all clinical laboratories in a geographic area (statewide 
in Maryland, Minnesota, New Mexico, and Tennessee, and metro Albany and Rochester areas in New York). In 
Georgia, all Campylobacter isolates received at the state laboratory from the Metropolitan Statistical Area (metro 
Atlanta area) were submitted to CDC. For that state, one isolate a week was selected at CDC (usually the first 
isolate received each week was selected, but otherwise isolates were randomly selected) from the collection of 
isolates from almost all clinical laboratories in metro Atlanta. In California, Colorado, Connecticut, and Oregon, 
one isolate a week was selected (usually the first isolate received each week was selected, but otherwise isolates 
were randomly selected) from one sentinel clinical laboratory. Sentinel clinical laboratories followed routine 
isolation practices for Campylobacter. No more than 53 Campylobacter isolates per state were included in the 
analyses; if more than one isolate was received in a week from a site, only the first isolate was included. 
 
 
TESTING OF SALMONELLA, SHIGELLA, AND ESCHERICHIA COLI O157 
 
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, Westlake, OH) to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial 
agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole (Table III). Before 2004, sulfamethoxazole was used instead of sulfisoxazole to represent the 
sulfonamides. Interpretive criteria defined by the Clinical and Laboratory Standards Institute (CLSI) were used 
when available.1 The resistance breakpoint for amikacin, according to CLSI guidelines, is an MIC of 64 µg/mL. 
For isolates that grew in all amikacin dilutions on the Sensititre® panel (MIC>4 µg/mL), E-Test (AB BIODISK, 




Table III: Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, Escherichia coli 
O157, and Campylobacter isolates, NARMS, 2004 
 
MIC Breakpoints (µg/mL) 
 
CLSI Subclass     Antimicrobial Agent Antimicrobial Agent 
Concentration 










      ≥8** 
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           4** 
 ≤4 
          ≤2** 
Kanamycin 8–64 ≥64 32 ≤16 
Aminoglycosides 
Streptomycin 32–64 ≥64  ≤32 
Aminopenicillins Ampicillin 1–32 ≥32 16 ≤8 
β-Lactamase inhibitor 
combinations 
Amoxicillin-Clavulanic acid 1/0.5–32/16 ≥32 / ≥16 16/8 ≤8 / ≤4 
Cephalosporin 
(1st generation) 
Cephalothin‡ 2–32 ≥32 16 ≤8 
Ceftiofur§ 0.12–8 ≥8 4 ≤2 Cephalosporins 
 (3rd generation) 
Ceftriaxone 0.25–64 ≥64 16–32 ≤8 
Cephamycins Cefoxitin 0.5–16 ≥32 16 ≤8 
Folate pathway inhibitors Trimethoprim- 
Sulfamethoxazole 
0.12/2.4–4/76 ≥4 / ≥76  ≤2 / ≤38 
Lincosamides Clindamycin 0.016–256† ≥8 4 ≤2 
Azithromycin 0.016–256† ≥8 4 ≤2 Macrolides 
Erythromycin 0.016–256† ≥32 16 ≤8 
Phenicols Chloramphenicol 2–32 
0.016–256†
≥32 16 ≤8 
Ciprofloxacin 0.015–4 
0.002–32†
≥4 2 ≤1 Quinolones 
Nalidixic acid 0.5–32 
0.016–256†
≥32 




         ≤16** 
Sulfamethoxazole 16–512 ≥512  ≤256 Sulfonamides¶
Sulfisoxazole 16–512 ≥512  ≤256 
Tetracyclines Tetracycline 4–16 
0.016–256†
≥16 8 ≤4 
 
* The resistance breakpoint for amikacin, according to Clinical and Laboratory Standards Institute (CLSI) guidelines, is 64 
µg/mL. For isolates that grew in all amikacin dilutions on the Sensititre® panel (minimum inhibitory concentration [MIC] >4 
µg/mL), E-Test (AB BIODISK, Solna, Sweden) was performed to determine amikacin MIC. The amikacin E-Test strip range of 
dilutions is 0.016–256 µg/mL. 
† E-test dilution range used for testing Campylobacter. 
‡ Cephalothin was not tested in 2004 but was tested in earlier years for Salmonella, Shigella, and E. coli O157. 
§ No CLSI breakpoints; resistance breakpoint used in NARMS is 8 µg/mL. 
¶ Sulfamethoxazole, which was tested during 1996–2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004. 
**Breakpoints for Campylobacter only 
 
 




Review of Salmonella isolates tested in NARMS during 1996–1998 gave conflicting cephalosporin susceptibility 
results. That is, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low ceftriaxone MIC 
and, in some cases, did not exhibit an elevated MIC to other β-lactams. Because these findings indicated that 
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some previously reported ceftiofur-resistant results were spurious, we retested, using the 2003 NARMS 
Sensititre® plate, isolates of Salmonella tested in NARMS during 1996–1998 that exhibited an MIC ≥2 μg/mL to 
ceftiofur or ceftriaxone. The retest results first were included in the 2003 NARMS annual report. Totals reported 




To distinguish serotypes Paratyphi B and Paratyphi B var L(+) tartrate-positive (formerly Salmonella Java), 
tartrate testing was performed at CDC on all Salmonella Paratyphi B isolates from 1996 to 2004 for which the 
tartrate result was not reported. Jordan's tartrate test was used to determine tartrate fermentation, and Kauffman's 
tartrate test subsequently was performed on isolates negative for tartrate fermentation by Jordan's tartrate test. 
Isolates negative for tartrate fermentation by both assays were categorized as serotype Paratyphi B. Isolates that 
were positive for tartrate fermentation by either assay were categorized as serotype Paratyphi B var L(+) tartrate-
positive and in this report are referred to as serotype Java. Confirmation of other biochemical reactions or somatic 
and flagellar antigens was not performed at CDC. 
 
Salmonella serotype was accepted as reported with few exceptions. As described above, tartrate testing was 
performed on all Salmonella Paratyphi B isolates for which the tartrate result was not reported. Because of 
increased submissions of Salmonella Typhimurium isolates lacking the second phase flagellar antigen (i.e., 
Salmonella I 4,[5],12:i:-), reports of such isolates tested in NARMS during 1996–2004 were reviewed, and isolates 
identified as serogroup B that exhibited first-phase flagellar antigen “I” but lacked a second phase are referred to 
in this report as “monophasic Typhimurium.” Serogroup B isolates for which the first-phase flagellar antigen was 




Testing of Campylobacter 
 
Identification/Speciation and Antimicrobial Susceptibility Testing 
 
In 2004, putative Campylobacter isolates were identified as Campylobacter jejuni or Campylobacter coli by 
polymerase chain reaction (PCR) using species-specific BAX® primers according to the manufacturer's 
instructions (DuPont Qualicon, Wilmington, DE). Isolates not identified as C. jejuni or C. coli were further 
characterized in conjunction with the CDC Campylobacter Reference Laboratory. 
 
During 1996–2003, isolates were confirmed as Campylobacter by dark-field microscopy and oxidase test. 
Identification of C. jejuni was performed using the hippurate hydrolysis test. Hippurate-positive isolates were 
identified as C. jejuni. Hippurate-negative isolates were identified by PCR as C. jejuni using a hippuricase gene-
based PCR assay,2 or as C. coli using a C. coli-specific ceuE PCR.3 Isolates determined to be neither C. jejuni 
nor C. coli were referred for identification to the CDC National Campylobacter Reference Laboratory. The 
methodology used during 1996–2003 was described in the 2003 annual report.4
 
In 2004, the E-test methodology (AB Biodisk, Solna, Sweden) was used to determine the MICs for eight 
antimicrobial agents: azithromycin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, 
nalidixic acid, and tetracycline (Table IIII). In this report, new CLSI interpretive criteria for erythromycin and 
revised NARMS criteria for azithromycin were used for 1997–2004.5 In previous annual reports, these CLSI 
interpretive criteria were not available, and NARMS used resistance breakpoints for azithromycin and 
erythromycin that were lower than the new and revised breakpoints used in this report.4  In addition, revised 
NARMS interpretive criteria, adopted from the FDA arm of NARMS, were used for clindamycin, gentamicin, and 




Known mechanisms of quinolone resistance in Campylobacter are expected to confer equivalent susceptibilities 
to nalidixic acid and ciprofloxacin. Similarly, known mechanisms of macrolide resistance are expected to confer 
equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting 








For all pathogens in this report, MICs were categorized as resistant, intermediate susceptibility (if applicable), and 
susceptible. Analysis was restricted to one isolate (per pathogen) per patient. Where established, CLSI 
interpretive criteria were used; ceftiofur resistance was defined as MIC ≥8 μg/mL (Table III). The 95% confidence 
interval (CI) for the percentage of resistant isolates are included in the MIC distribution tables. The 95% CI was 
calculated using the Clopper-Pearson exact method.6 Multidrug resistance by CLSI antimicrobial subclass was 
defined as resistance to two or more subclasses. 
 
When describing results for several years, multidrug resistance for Salmonella and E. coli O157 isolates was 
limited to the 13 agents tested in all years from 1996 through 2004 (amoxicillin-clavulanic acid, ampicillin, 
ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, 
sulfamethoxazole, tetracycline, and trimethoprim-sulfamethoxazole). For Salmonella Typhi and Shigella, results 
for several years included 14 agents tested in all years from 1999 through 2004 (13 antimicrobial agents 
mentioned above and amikacin). Similarly, when describing multidrug resistance for several years for 
Campylobacter isolates, multidrug resistance was limited to the six agents tested in all years from 1997 through 
2004 (chloramphenicol, ciprofloxacin, clindamycin, erythromycin, nalidixic acid, and tetracycline). 
 
Logistic regression was performed to compare the change in antimicrobial resistance among Salmonella and 
Campylobacter isolates tested in NARMS during 2004 with that of previous years for the following: 
1. Non-Typhi Salmonella: resistance to nalidixic acid, resistance to ceftiofur, resistance to one or more CLSI 
subclass. 
2. Salmonella Typhimurium: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, 
and tetracycline (R-Type ACSSuT). 
3. Salmonella Enteritidis: resistance to nalidixic acid. 
4. Salmonella Newport: resistance to at least ACSSuT, amoxicillin-clavulanic acid, and ceftiofur, with decreased 
susceptibility to ceftriaxone (MDR-AmpC). 
5. Salmonella Typhi: resistance to nalidixic acid. 
6. Campylobacter species: resistance to ciprofloxacin. 
7. Campylobacter jejuni: resistance to ciprofloxacin. 
 
The final regression models for non-Typhi Salmonella, and final models for serotypes Typhimurium and Typhi, 
adjusted for site using the nine Public Health Service geographic regions described in the Public Health 
Laboratory Information System (PHLIS [http://www.cdc.gov/ncidod/dbmd/phlisdata/]) based on the patient’s state 
of residence. The PHLIS regions are East North Central, East South Central, Mid-Atlantic, Mountain, New 
England, Pacific, South Atlantic, West North Central, and West South Central. For all regression models that 
adjusted for site, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional 
maximum likelihood estimation. In the final regression models for serotypes Enteritidis and Newport, which 
included only year and used unconditional exact methods, the maximum likelihood estimate of the OR did not 
exist; only the 95% CIs are reported.  For Campylobacter, the final regression models adjusted for site using four 
aggregated regions based on patient’s state of residence. All analyses included observations from only those 
state and local health departments that had submitted isolates for at least 3 years. The adequacy of model fit was 
assessed in several ways. The significance of the main effect of year was assessed using the likelihood ratio test. 
The likelihood ratio test was also used to test for significance of interaction between site and year, although the 
power of the test to detect a single site-specific interaction was low. The Hosmer and Lemeshow goodness-of-fit 
test also was used.7 Finally, residual analysis was performed to examine the influence of individual observations. 






RESULTS FOR 2004 
 
 
1. NON-TYPHI SALMONELLA 
 
In 2004, CDC received 1832 non-Typhi Salmonella isolates, of which 1808 (98.7%) were viable and tested for 
antimicrobial susceptibility.  Of these 1808 isolates, 15 isolates were excluded from the analysis because they 
were submissions from the same patient, leaving 1793 isolates for analysis. (Table I). 
 
Fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) are commonly used 
to treat severe Salmonella infections. Nalidixic acid is an elementary quinolone; resistance to nalidixic acid 
correlates with decreased susceptibility to ciprofloxacin and possible treatment failure. Ceftiofur is a third-
generation cephalosporin used in food animals in the United States; resistance to ceftiofur correlates with 
decreased susceptibility to ceftriaxone. In 2004, the prevalence of resistance among Salmonella isolates was 
2.6% for quinolones (represented by nalidixic acid) and 3.4% for third-generation cephalosporins (represented by 
ceftiofur) (Table 1.1). 
 
The antimicrobial agents with the highest prevalence of resistance were tetracycline (13.5%), sulfisoxazole 
(13.2%), ampicillin (12.0%), and streptomycin (11.8%). (Sulfisoxazole replaced sulfamethoxazole to represent the 
sulfonamides in the 2004 NARMS panel.) 
 
The prevalence of nalidixic acid resistance increased from 0.4% (5/1324) in 1996 to 2.6% (47/1793) in 2004 
(Table 1.2); a statistically significant increase (OR=9.2, 95% CI [3.6, 23.8]). The prevalence of ceftiofur resistance 
increased from 0.2% (2/1324) in 1996 to 3.4% (61/1793) in 2004; a statistically significant increase (OR=34.5, 
95% CI [8.3, 142.7]).  
 
The proportion of resistance to most of the agents tested in 2004 was lower than in 2003, including ampicillin, 
amoxicillin-clavulanic acid, ceftiofur, cefoxitin, chloramphenicol, tetracycline, and streptomycin. However, for 
ceftiofur, resistance increased since 1996. 
 
Of the 1783 non-Typhi Salmonella isolated in 2004, 79.6% (1427) had no detected resistance, a slight increase 
from the 77.7% in 2003 (Table 1.3). In 2004, 366 (20.4%) were resistant to one or more CLSI subclass; 269 
(15.0%), to two or more subclasses; 210 (11.7%), to three or more subclasses; 168 (9.4%), to four or more 
subclasses; and 146 (8.1%), to five or more subclasses.  There was a statistically significant decline in resistance 
to one or more subclass from 33.8% in 1996 to 20.4% in 2004 (OR=0.6, 95% CI [0.5, 0.7]) (Table 1.3). 
 
 
In 2004, the most common multidrug-resistant phenotype (7.1%) among non-Typhi Salmonella isolates was 
resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline 
(R-Type ACSSuT). The proportion of isolates with R-Type ACSSuT was lower in 2004 than in 2003. Overall, 
however, the prevalence of R-Type ACSSuT did not change among non-Typhi Salmonella isolates from 1996 to 
2004. Another common multidrug-resistant phenotype among non-Typhi Salmonella isolates was resistance to at 
least ACSSuT, amoxicillin-clavulanic acid, and ceftiofur and decreased susceptibility to ceftriaxone (MIC ≥2 
µg/mL) (MDR-AmpC) (2.3%). The prevalence of MDR-AmpC increased from 0% (0/1324) in 1996 to 2.3% 
(42/1793) in 2004.  Seven (0.4%) isolates were resistant to a quinolone (nalidixic acid) and third-generation 
cephalosporin (ceftiofur) (Table 1.3); this pattern was first detected in 1997. 
 
 Serotypes were identified for a higher proportion of isolates in NARMS (95.8%) than in the Public Health 
Laboratory Information System (PHLIS) (90.4%) (Table 1.4). The 20 most common serotypes accounted for 
81.1% of isolates in NARMS and for 75.1% in PHLIS. The five most common serotypes accounted for 58.1% of 
isolates in NARMS and 53.0% in PHLIS.
Table 1.1: Minimum inhibitory concentrations (MICs) and resistance of non-Typhi Salmonella isolates to antimicrobial agents, 2004 (N=1793)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.2] 7.8 69.5 20.0 2.5 0.2
Gentamicin 0.4 1.3 [0.9–2.0] 68.4 27.7 2.0 0.2 0.1 0.4 0.6 0.8
Kanamycin 0.2 2.8 [2.1–3.7] 96.7 0.3 0.2 0.2 2.6
Streptomycin NA 11.8 [10.4–13.4] 88.2 5.7 6.1
Aminopenicillins Ampicillin 0.1 12.0 [10.6–13.6] 60.4 25.8 1.7 0.1 0.1 12.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 5.7 3.7 [2.9–4.7] 83.8 3.8 0.4 2.5 5.7 0.8 2.9
Ceftiofur 0.3 3.4 [2.6–4.3] 0.6 1.5 76.2 17.6 0.4 0.3 0.1 3.3
Ceftriaxone 2.6 0.6 [0.3–1.0] 96.4 0.2 0.1 0.2 1.4 1.2 0.5 0.1
Cephamycins Cefoxitin 0.3 3.5 [2.7–4.4] 0.2 25.5 56.1 12.7 1.8 0.3 1.3 2.1
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.8 [1.2–2.5] 76.4 21.0 0.6 0.1 0.2 0.1 1.7
Phenicols Chloramphenicol 0.9 7.6 [6.4–8.9] 2.1 45.1 44.3 0.9 7.6
Ciprofloxacin 0.1 0.2 [0.1–0.6] 95.8 1.4 0.1 1.1 0.9 0.4 0.1 0.2
Nalidixic Acid NA 2.6 [1.9–3.5] 0.1 0.4 26.0 69.2 1.5 0.2 0.2 2.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 13.2 [11.7–14.9] 19.3 55.7 11.5 0.2 0.1 13.2
Tetracyclines Tetracycline 0.3 13.5 [11.9–15.2] 86.2 0.3 1.4 4.5 7.6
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations 
represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Percent of all isolates with MIC (µg/mL)§
Quinolones
Aminoglycosides






Year 1996 1997 1998 1999 2000 2001 2002 2003 2004




Amikacin Not 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 1 0 0 0 0 0
Gentamicin 4.8% 2.9% 2.8% 2.1% 2.7% 1.9% 1.3% 1.4% 1.3%
(MIC ≥ 16) 63 38 41 32 37 27 27 26 24
Kanamycin 5.0% 5.1% 5.7% 4.3% 5.6% 4.8% 3.8% 3.4% 2.8%
(MIC ≥ 64) 66 67 83 65 77 68 76 64 50
Streptomycin 20.6% 21.4% 18.6% 16.8% 16.3% 17.0% 13.2% 15.0% 11.8%
(MIC ≥ 64) 273 278 272 251 224 241 265 279 212
Ampicillin 20.7% 18.3% 16.5% 15.6% 15.9% 17.4% 12.9% 13.6% 12.0%
(MIC ≥ 32) 274 238 241 233 219 247 259 254 216
Amoxicillin-clavulanic acid 1.1% 1.0% 1.7% 2.3% 3.9% 4.7% 5.3% 4.6% 3.7%
(MIC ≥ 32) 15 13 25 35 54 66 106 86 67
Cephalothin 2.9% 2.2% 2.3% 3.6% 4.0% 4.0% 5.0% 5.4% Not
(MIC ≥ 32) 39 29 33 54 55 57 101 100 Teste
Ceftiofur 0.2% 0.5% 0.8% 2.0% 3.2% 4.1% 4.3% 4.5% 3.4%
(MIC ≥ 8) 2 6 12 30 44 58 87 83 61
Ceftriaxone 0.0% 0.1% 0.0% 0.3% 0.0% 0.0% 0.2% 0.4% 0.6%
(MIC ≥ 64) 0 1 0 5 0 0 4 8 10
Cefoxitin Not Not Not Not 3.2% 3.4% 4.3% 4.2% 3.5%
(MIC ≥ 32) Tested Tested Tested Tested 44 48 86 79 62
Trimethoprim-sulfamethoxazole 3.9% 1.8% 2.3% 2.1% 2.1% 2.0% 1.4% 1.9% 1.8%
(MIC ≥ 4) 51 24 34 31 29 28 28 36 32
Chloramphenicol 10.6% 10.1% 9.9% 9.2% 10.1% 11.6% 8.6% 10.0% 7.6%
(MIC ≥ 32) 140 131 145 138 139 164 172 187 136
Ciprofloxacin 0.0% 0.0% 0.1% 0.1% 0.4% 0.2% 0.0% 0.2% 0.2%
(MIC ≥ 4) 0 0 1 1 5 3 1 3 4
Nalidixic Acid 0.4% 0.9% 1.4% 1.0% 2.5% 2.6% 1.8% 2.3% 2.6%
(MIC ≥ 32) 5 12 20 15 34 37 36 42 47
Sulfamethoxazole/Sulfisoxazole* 20.3% 22.8% 19.4% 18.0% 17.1% 17.7% 12.8% 15.0% 13.2%
(MIC ≥ 512) 269 297 283 270 235 251 258 280 237
Tetracycline 24.2% 21.7% 20.2% 19.4% 18.6% 19.7% 14.9% 16.3% 13.5%
(MIC ≥ 16) 320 282 295 290 256 280 299 303 242



















Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 1324 1301 1460 1497 1377 1419 2008 1864 1793
% % % % % % % % %
n n n n n n n n n
No resistance detected 66.2% 68.4% 72.9% 74.1% 74.4% 72.3% 79.0% 77.7% 79.6%
 876 890 1064 1109 1024 1026 1586 1449 1427
Resistance ≥1CLSI subclass* 33.8% 31.6% 27.1% 25.9% 25.6% 27.7% 21.0% 22.3% 20.4%
 448 411 396 388 353 393 422 415 366
Resistance ≥2 CLSI subclasses* 27.0% 24.1% 22.6% 20.4% 20.2% 22.1% 15.8% 17.7% 15.0%
 358 314 330 306 278 314 318 330 269
Resistance ≥3 CLSI subclasses* 18.1% 17.7% 16.7% 15.1% 15.6% 16.8% 12.2% 14.3% 11.7%
 240 230 244 226 215 239 244 266 210
Resistance ≥4 CLSI subclasses* 13.7% 13.7% 13.1% 12.3% 12.9% 14.2% 9.9% 11.6% 9.4%
 181 178 191 184 178 202 199 216 168
Resistance ≥5 CLSI subclasses* 10.0% 9.9% 10.1% 8.7% 9.9% 10.5% 8.3% 9.9% 8.1%
 132 129 147 130 137 149 167 185 146
At least ACSSuT† 8.8% 9.5% 8.9% 8.4% 8.9% 10.0% 7.8% 9.3% 7.1%
 116 124 130 126 122 142 156 173 128
At least ACSuTm‡ 0.8% 0.4% 0.9% 1.0% 1.0% 0.5% 1.0% 1.2% 0.6%
 10 5 13 15 14 7 21 23 10
At least ACSSuTAuCf§ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3%
 0 4 5 23 36 36 67 60 42
At least MDR-AmpC¶ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3%
 0 4 5 23 36 36 67 60 42
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.2% 0.1% 0.1% 0.3% 0.3% 0.2% 0.2% 0.4%
 0 2 1 1 4 4 5 4 7
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
Table 1.3: Resistance patterns of non-Typhi Salmonella  isolates, 1996–2004
 
 
Rank Serotype N (%) Rank Serotype N (%)
1 Typhimurium 382 (21.3%) 1 Typhimurium 6855 (19.4%)
2 Enteritidis 271 (15.1%) 2 Enteritidis 5028 (14.2%)
3 Newport 190 (10.6%) 3 Newport 3329 (9.4%)
4 Javiana 106 (5.9%) 4 Javiana 1776 (5.0%)
5 Heidelberg 93 (5.2%) 5 Heidelberg 1758 (5.0%)
6 Montevideo 50 (2.8%) 6 Montevideo 874 (2.5%)
7 I 4,[5],12:i:- (monophasic Typhimurium) 36 (2.0%) 7 I 4,[5],12:i:- (monophasic Typhimurium) 739 (2.1%)
8 Braenderup 33 (1.8%) 8 Muenchen 739 (2.1%)
9 Oranienburg 32 (1.8%) 9 Saintpaul 695 (2.0%)
10 Muenchen 32 (1.8%) 10 Braenderup 684 (1.9%)
11 Saintpaul 32 (1.8%) 11 Infantis 588 (1.7%)
12 Paratyphi B var. L(+) tartrate+ 30 (1.7%) 12 Mississippi 558 (1.6%)
13 Infantis 29 (1.6%) 13 Oranienburg 495 (1.4%)
14 Thompson 26 (1.5%) 14 Thompson 494 (1.4%)
15 Mississippi 24 (1.3%) 15 Berta 409 (1.2%)
16 Agona 24 (1.3%) 16 Agona 407 (1.2%)
17 Hartford 18 (1.0%) 17 Paratyphi B var. L(+) tartrate+ 354 (1.0%)
18 Anatum 16 (0.9%) 18 Hadar 277 (0.8%)
19 Berta 14 (0.8%) 19 Anatum 250 (0.7%)
20 Mbandaka 14 (0.8%) 20 Paratyphi B 239 (0.7%)
Subtotal 1452 (81.0%) Subtotal 26548 (75.1%)
All Other serotypes 266 (14.8%) All Other serotypes 5423 (15.3%)
Unknown serotype 16 (0.9%) Unknown serotype 1999 (5.7%)
Partially serotyped 23 (1.3%) Partially serotyped 1324 (3.7%)
Rough/Nonmotile isolates 36 (2.0%) Rough/Nonmotile isolates 61 (0.2%)
Subtotal 341 (19.0%) Subtotal 8807 (24.9%)
Grand Total 1793 (100.0%) Grand Total 35355 (100.0%)









A. Salmonella Typhimurium 
 
In 2004, Typhimurium was the most common Salmonella serotype in NARMS, accounting for 21.3% (382/1793) 
of non-Typhi Salmonella isolates (Table 1.5). Of the 382 Salmonella Typhimurium isolates tested, resistance was 
highest to sulfisoxazole (35.9%), ampicillin (31.9%), streptomycin (31.7%), tetracycline (30.1%), and 
chloramphenicol (24.1%). The prevalence of resistance among clinically important antimicrobial subclasses was 
0.5% for quinolones (represented by nalidixic acid) and 4.5% for third-generation cephalosporins (represented by 
ceftiofur). 
 
The most dramatic increase over time occurred with ceftiofur resistance—from no resistance in 1996 to 4.5% in 
2004 (Table 1.6). Resistance to many of the other antimicrobial agents decreased since 1996 (Table 1.6). 
Resistance to tetracycline decreased from 49.3% in 1996 to 30.1% in 2004; ampicillin, from 50.0% to 31.9%; 
streptomycin, from 51.6% to 31.7%; chloramphenicol, from 39.9% to 24.1%; and gentamicin, from 4.2% to 2.1%. 
 
Of the 382 Salmonella Typhimurium isolates tested during 2004, 60.7% (232) had no detected resistance, a slight 
increase from the 55.3% of isolates in 2003 (Table 1.7). In 2004, 37.2% (142/382) were resistant to two or more 
CLSI subclasses, compared with 40.9% in 2003. Similarly, in 2004, 24.3% (93/382) were resistant to at least five 
subclasses, compared with 27.5% in 2003. 
 
In 2004, the most common multidrug-resistant phenotype among Salmonella Typhimurium was R-Type ACSSuT 
(23.3% of isolates). For Salmonella Typhimurium, R-Type ACSSuT commonly is associated with definitive phage 
type 104.  Since 1996, the prevalence of R-Type ACSSuT among Salmonella Typhimurium decreased from 
33.7% to 23.3%. In the logistic regression model, this decrease was statistically significant (OR=0.6, 95% CI [0.4, 
0.8]). 
 
One (0.3%) serotype Typhimurium isolate was resistant to both quinolones and third-generation cephalosporins in 
2004. Since 1996, six Salmonella Typhimurium isolates have shown this multidrug resistance pattern. 
 
Table 1.5: Minimum inhibitory concentrations (MICs) and resistance of  Salmonella Typhimurium isolates to antimicrobial agents, 2004 (N=382)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.0] 1.8 74.3 21.7 2.1
Gentamicin 0.0 2.1 [0.9–4.1] 64.1 32.5 1.0 0.3 0.5 1.6
Kanamycin 0.0 5.8 [3.6–8.6] 93.7 0.5 0.3 5.5
Streptomycin NA 31.7 [27.0–36.6] 68.3 20.4 11.3
Aminopenicillins Ampicillin 0.0 31.9 [27.3–36.9] 43.2 23.3 1.6 31.9
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 21.2 4.7 [2.8–7.3] 66.2 2.1 5.8 21.2 0.3 4.5
Ceftiofur 0.0 4.5 [2.6–7.0] 0.3 1.0 77.2 16.2 0.8 4.5
Ceftriaxone 3.4 0.8 [0.2–2.3] 95.5 0.3 2.9 0.5 0.8
Cephamycins Cefoxitin 0.3 4.7 [2.8–7.3] 0.3 19.6 66.2 6.5 2.4 0.3 2.6 2.1
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 2.6 [1.3–4.8] 63.4 33.5 0.3 0.3 2.6
Phenicols Chloramphenicol 0.3 24.1 [19.9–28.7] 1.8 38.2 35.6 0.3 24.1
Ciprofloxacin 0.0 0.0 [0.0–1.0] 97.9 1.3 0.5 0.3
Nalidixic Acid NA 0.5 [0.1–1.9] 0.5 24.6 72.8 1.3 0.3 0.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 35.9 [31.0–40.9] 11.8 49.2 2.9 0.3 35.9
Tetracyclines Tetracycline 0.0 30.1 [25.5–35.0] 69.9 5.2 15.2 9.7
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides







Year 1996 1997 1998 1999 2000 2001 2002 2003 2004




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0
Gentamicin 4.2% 4.6% 3.7% 2.2% 2.6% 1.5% 2.3% 2.0% 2.1%
(MIC ≥ 16) 13 15 14 8 8 5 9 8 8
Kanamycin 14.4% 15.5% 15.9% 13.0% 13.2% 8.3% 7.6% 7.2% 5.8%
(MIC ≥ 64) 44 51 60 47 40 27 30 29 22
Streptomycin 51.6% 55.2% 47.2% 43.1% 39.3% 40.0% 31.8% 35.0% 31.7%
(MIC ≥ 64) 158 181 178 156 119 130 125 141 121
Ampicillin 50.0% 50.3% 45.1% 41.2% 41.9% 42.5% 33.6% 35.5% 31.9%
(MIC ≥ 32) 153 165 170 149 127 138 132 143 122
Amoxicillin-clavulanic acid 2.6% 3.4% 4.5% 2.8% 6.3% 6.2% 7.6% 5.2% 4.7%
(MIC ≥ 32) 8 11 17 10 19 20 30 21 18
Cephalothin 2.0% 4.3% 4.0% 4.4% 4.3% 3.1% 5.6% 6.0% Not
(MIC ≥ 32) 6 14 15 16 13 10 22 24 Tested
Ceftiofur 0.0% 1.5% 1.9% 1.9% 3.6% 3.1% 4.3% 4.7% 4.5%
(MIC ≥ 8) 0 5 7 7 11 10 17 19 17
Ceftriaxone 0.0% 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.2% 0.8%
(MIC ≥ 64) 0 1 0 1 0 0 1 1 3
Cefoxitin Not Not Not Not 3.6% 3.1% 4.3% 4.2% 4.7%
(MIC ≥ 32) Tested Tested Tested Tested 11 10 17 17 18
Trimethoprim-sulfamethoxazole 4.6% 3.0% 4.5% 2.8% 3.6% 2.5% 2.3% 3.5% 2.6%
(MIC ≥ 4) 14 10 17 10 11 8 9 14 10
Chloramphenicol 39.9% 36.0% 33.4% 28.7% 30.7% 31.7% 23.2% 27.5% 24.1%
(MIC ≥ 32) 122 118 126 104 93 103 91 111 92
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 1 0 0 0
Nalidixic Acid 0.3% 0.9% 0.5% 0.0% 1.3% 0.6% 1.3% 1.2% 0.5%
(MIC ≥ 32) 1 3 2 0 4 2 5 5 2
Sulfamethoxazole/Sulfisoxazole* 53.3% 56.7% 49.6% 45.6% 45.2% 43.1% 32.1% 38.2% 35.9%
(MIC ≥ 512) 163 186 187 165 137 140 126 154 137
Tetracycline 49.3% 52.4% 45.9% 41.7% 43.2% 43.4% 31.8% 37.7% 30.1%
(MIC ≥ 16) 151 172 173 151 131 141 125 152 115












Table 1.6: Percentage and number of Salmonella  Typhimurium isolates resistant to antimicrobial agents, 1996–2004
 
 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 306 328 377 362 303 325 393 403 382
% % % % % % % % %
n n n n n n n n n
No resistance detected 37.9% 39.0% 46.9% 50.6% 49.5% 49.2% 60.3% 55.3% 60.7%
 116 128 177 183 150 160 237 223 232
Resistance ≥1CLSI subclass* 62.1% 61.0% 53.1% 49.4% 50.5% 50.8% 39.7% 44.7% 39.3%
 190 200 200 179 153 165 156 180 150
Resistance ≥2 CLSI subclasses* 56.2% 56.7% 50.9% 46.1% 46.9% 48.0% 36.1% 40.9% 37.2%
 172 186 192 167 142 156 142 165 142
Resistance ≥3 CLSI subclasses* 51.0% 52.4% 47.2% 43.1% 43.2% 41.8% 32.3% 36.5% 31.4%
 156 172 178 156 131 136 127 147 120
Resistance ≥4 CLSI subclasses* 45.4% 47.9% 42.7% 38.4% 39.6% 38.2% 28.5% 31.8% 28.0%
 139 157 161 139 120 124 112 128 107
Resistance ≥5 CLSI subclasses* 35.6% 36.0% 34.0% 27.9% 30.4% 29.8% 23.4% 27.5% 24.3%
 109 118 128 101 92 97 92 111 93
At least ACSSuT† 33.7% 35.1% 31.8% 27.6% 27.7% 29.5% 21.4% 25.8% 23.3%
 103 115 120 100 84 96 84 104 89
At least ACSuTm‡ 2.0% 0.6% 2.7% 2.2% 1.7% 0.9% 2.0% 3.2% 1.6%
 6 2 10 8 5 3 8 13 6
At least ACSSuTAuCf§ 0.0% 1.2% 1.1% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6%
 0 4 4 2 6 4 7 9 10
At least MDR-AmpC¶ 0.0% 1.2% 1.1% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6%
 0 4 4 2 6 4 7 9 10
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.5% 0.0% 0.3%
 0 1 0 0 1 1 2 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   




B. Salmonella Enteritidis 
 
In 2004, Salmonella Enteritidis was the second most common serotype identified in NARMS, accounting for 
15.1% (271/1793) of non-Typhi Salmonella isolates (Table 1.8). Among Salmonella Enteritidis isolates tested in 
2004, resistance was uncommon.  The most dramatic increase occurred with nalidixic acid.  There was a 
statistically significant increase in nalidixic acid resistance from 0.9% in 1996 to 6.6% in 2004 (95% CI [2.3, 49.3]) 
(Table 1.9).  Salmonella Enteritidis was the most prevalent (38.3%) non-Typhi Salmonella serotype that had 
resistance to nalidixic acid (Table 1.14). 
 
Most (87.1%) of the Salmonella Enteritidis isolates tested in 2004 had no detected resistance (Table 1.10).  
Multidrug resistance was uncommon.  
 
Table 1.8: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Enteriditis isolates to antimicrobial agents, 2004 (N=271)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.4] 23.6 64.9 9.2 2.2
Gentamicin 0.0 0.4 [0.0–2.0] 85.2 12.9 1.1 0.4 0.4
Kanamycin 0.0 0.7 [0.1–2.6] 99.3 0.7
Streptomycin NA 2.2 [0.8–4.8] 97.8 1.5 0.7
Aminopenicillins Ampicillin 0.0 4.1 [2.0–7.1] 57.2 38.4 0.4 0.4 3.7
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 1.5 0.0 [0.0–1.4] 91.9 4.4 0.7 1.5 1.5
Ceftiofur 0.4 0.0 [0.0–1.4] 1.1 0.7 66.1 31.7 0.4
Ceftriaxone 0.0 0.0 [0.0–1.4] 99.6 0.4
Cephamycins Cefoxitin 0.0 0.0 [0.0–1.4] 0.4 23.2 69.4 5.9 1.1
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.0 [0.0–1.4] 81.2 18.1 0.7
Phenicols Chloramphenicol 0.4 0.4 [0.0–2.0] 1.8 51.3 46.1 0.4 0.4
Ciprofloxacin 0.4 0.0 [0.0–1.4] 93.0 0.4 3.3 3.0 0.4
Nalidixic Acid NA 6.6 [4.0–10.3] 0.4 0.4 11.1 80.4 1.1 0.4 6.3
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 1.8 [0.6–4.3] 15.9 77.1 4.8 0.4 1.8
Tetracyclines Tetracycline 1.1 3.3 [1.5–6.2] 95.6 1.1 0.4 3.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides







Year 1996 1997 1998 1999 2000 2001 2002 2003 2004




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0
Gentamicin 4.8% 0.3% 0.4% 0.0% 0.3% 0.0% 0.3% 0.4% 0.4%
(MIC ≥ 16) 17 1 1 0 1 0 1 1 1
Kanamycin 0.0% 0.7% 0.4% 0.4% 0.3% 0.7% 0.3% 0.0% 0.7%
(MIC ≥ 64) 0 2 1 1 1 2 1 0 2
Streptomycin 2.0% 4.3% 1.6% 2.2% 0.0% 1.4% 1.8% 1.2% 2.2%
(MIC ≥ 64) 7 13 4 6 0 4 6 3 6
Ampicillin 20.5% 11.3% 6.1% 10.8% 7.5% 8.7% 7.1% 2.3% 4.1%
(MIC ≥ 32) 72 34 15 29 24 24 24 6 11
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.4% 0.0% 1.4% 0.6% 0.0% 0.0%
(MIC ≥ 32) 2 0 0 1 0 4 2 0 0
Cephalothin 4.0% 1.3% 0.0% 1.9% 0.9% 1.1% 0.6% 1.2% Not
(MIC ≥ 32) 14 4 0 5 3 3 2 3 Teste
Ceftiofur 0.0% 0.3% 0.0% 0.4% 0.0% 2.2% 0.0% 0.0% 0.0%
(MIC ≥ 8) 0 1 0 1 0 6 0 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Cefoxitin Not Not Not Not 0.0% 0.4% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested Tested Tested Tested 0 1 0 0 0
Trimethoprim-sulfamethoxazole 6.6% 1.3% 0.8% 0.7% 0.0% 0.7% 0.6% 0.8% 0.0%
(MIC ≥ 4) 23 4 2 2 0 2 2 2 0
Chloramphenicol 0.0% 0.7% 0.0% 0.4% 0.0% 0.0% 0.6% 0.4% 0.4%
(MIC ≥ 32) 0 2 0 1 0 0 2 1 1
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.9% 1.7% 2.0% 2.2% 2.2% 4.3% 3.9% 4.7% 6.6%
(MIC ≥ 32) 3 5 5 6 7 12 13 12 18
Sulfamethoxazole/Sulfisoxazole* 8.5% 9.0% 2.0% 3.0% 0.9% 2.2% 1.8% 1.2% 1.8%
(MIC ≥ 512) 30 27 5 8 3 6 6 3 5
Tetracycline 16.8% 9.6% 6.6% 8.2% 1.9% 1.8% 4.5% 1.6% 3.3%
(MIC ≥ 16) 59 29 16 22 6 5 15 4 9
*Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.















Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 351 301 244 269 319 276 337 257 271
% % % % % % % % %
n n n n n n n n n
No resistance detected 73.5% 77.4% 87.7% 83.6% 89.0% 86.6% 87.2% 91.8% 87.1%
 258 233 214 225 284 239 294 236 236
Resistance ≥1CLSI subclass* 26.5% 22.6% 12.3% 16.4% 11.0% 13.4% 12.8% 8.2% 12.9%
 93 68 30 44 35 37 43 21 35
Resistance ≥2 CLSI subclasses* 19.1% 9.6% 6.6% 8.6% 1.9% 4.7% 4.2% 2.3% 3.0%
 67 29 16 23 6 13 14 6 8
Resistance ≥3 CLSI subclasses* 8.0% 3.0% 0.8% 1.1% 0.3% 2.9% 2.4% 0.8% 1.1%
 28 9 2 3 1 8 8 2 3
Resistance ≥4 CLSI subclasses* 4.6% 1.3% 0.0% 0.7% 0.0% 1.8% 1.5% 0.4% 0.7%
 16 4 0 2 0 5 5 1 2
Resistance ≥5 CLSI subclasses* 1.7% 0.7% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.7%
 6 2 0 1 0 0 1 1 2
At least ACSSuT† 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.4%
 0 1 0 1 0 0 1 1 1
At least ACSuTm‡ 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.0% 0.4% 0.0%
 0 1 0 1 0 0 0 1 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 1 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 1 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.3% 0.0% 0.0% 0.3% 0.0% 0.0% 0.4% 0.0%
 0 1 0 0 1 0 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
Table 1.10: Resistance patterns of Salmonella  Enteritidis isolates, 1996–2004
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C. Salmonella Newport 
 
In 2004, Newport was the third most commonly isolated Salmonella serotype in NARMS, accounting for 10.5% 
(189/1793) of non-Typhi Salmonella isolates (Table 1.11). Of the 190 Salmonella Newport isolates, resistance 
was highest to sulfisoxazole (16.8%), tetracycline (16.8%), ampicillin (15.8%), streptomycin (15.8%), amoxicillin-
clavulanic acid (15.3%), ceftiofur (15.3%), cefoxitin (15.3%), and chloramphenicol (15.3%). The prevalence of 
resistance among clinically important antimicrobial subclasses was 0.5% for quinolones (represented by nalidixic 
acid) and 15.3% for third-generation cephalosporins (represented by ceftiofur).
 
Ceftiofur resistance was first noted in one isolate (1.3%) in 1998; it increased to 18.2% in 1999, peaked at 27.4% 
in 2001, and declined to 15.3% in 2004 (Table 1.12). Salmonella Newport was the most prevalent (47.5%) non-
Typhi Salmonella serotype that had resistance to ceftiofur (Table 1.14).  
 
In contrast to other common serotypes, the percentage of Salmonella Newport isolates with no detected 
resistance declined from 86.3% in 1996 and 74.2% in 2003 (Table 1.13). However, the percentage of Salmonella 
Newport isolates with no detected resistance was higher in 2004 (82.1%) than in 2003 (73.9%). In addition, 
resistance to at least five subclasses of antimicrobial agents increased from 5.9% in 1996 to 14.7% in 2004, but 
decreased from the peak in 2001, similar to the trend in ceftiofur resistance. 
 
In 2004, the most common multidrug-resistant phenotype among serotype Newport isolates was MDR-AmpC; 
(14.7% of isolates).  This phenotype has increased since 1996, similar to the trend in ceftiofur resistance (Table 
1.13). In the logistic regression model, the increase in MDR-AmpC from 1996 to 2004 was statistically significant 
(95% CI [3.4, infinity]). 
 
Table 1.11: Minimum inhibitory concentrations (MICs) and resistance of  Salmonella Newport itsolates to antimicrobial agents, 2004 (N=190)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.9] 6.8 72.1 17.9 2.6 0.5
Gentamicin 0.0 0.5 [0.0–2.9] 78.4 19.5 1.6 0.5
Kanamycin 0.0 2.6 [0.9–6.0] 97.4 2.6
Streptomycin NA 15.8 [10.9–21.8] 84.2 15.8
Aminopenicillins Ampicillin 0.0 15.8 [10.9–21.8] 57.4 25.8 1.1 15.8
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.0 15.3 [10.5–21.2] 81.1 2.1 0.5 1.1 3.7 11.6
Ceftiofur 0.0 15.3 [10.5–21.2] 0.5 0.5 73.7 10.0 0.5 14.7
Ceftriaxone 12.1 2.6 [0.9–6.0] 84.2 1.1 4.7 7.4 2.1 0.5
Cephamycins Cefoxitin 0.0 15.3 [10.5–21.2] 23.7 55.8 3.7 1.6 3.2 12.1
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 2.1 [0.6–5.3] 73.2 23.2 0.5 0.5 0.5 2.1
Phenicols Chloramphenicol 0.0 15.3 [10.5–21.2] 2.1 54.7 27.9 15.3
Ciprofloxacin 0.0 0.0 [0.0–1.9] 98.4 1.1 0.5
Nalidixic Acid NA 0.5 [0.0–2.9] 1.1 34.7 62.1 1.6 0.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 16.8 [11.8–22.9] 5.8 42.1 34.7 0.5 16.8
Tetracyclines Tetracycline 0.0 16.8 [11.8–22.9] 83.2 4.2 12.6
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides







Year 1996 1997 1998 1999 2000 2001 2002 2003 2004




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0
Gentamicin 5.9% 4.3% 0.0% 0.0% 2.5% 3.2% 3.3% 3.2% 0.5%
(MIC ≥ 16) 3 2 0 0 3 4 8 7 1
Kanamycin 2.0% 0.0% 1.3% 1.0% 5.0% 7.3% 9.6% 4.5% 2.6%
(MIC ≥ 64) 1 0 1 1 6 9 23 10 5
Streptomycin 7.8% 4.3% 2.6% 19.2% 24.0% 31.5% 24.7% 23.5% 15.8%
(MIC ≥ 64) 4 2 2 19 29 39 59 52 30
Ampicillin 5.9% 6.5% 2.6% 18.2% 23.1% 29.8% 24.3% 22.2% 15.8%
(MIC ≥ 32) 3 3 2 18 28 37 58 49 30
Amoxicillin-clavulanic acid 2.0% 0.0% 2.6% 18.2% 22.3% 26.6% 22.2% 21.3% 15.3%
(MIC ≥ 32) 1 0 2 18 27 33 53 47 29
Cephalothin 3.9% 4.3% 2.6% 18.2% 22.3% 26.6% 22.2% 21.7% Not
(MIC ≥ 32) 2 2 2 18 27 33 53 48 Tested
Ceftiofur 0.0% 0.0% 1.3% 18.2% 22.3% 27.4% 22.2% 21.7% 15.3%
(MIC ≥ 8) 0 0 1 18 27 34 53 48 29
Ceftriaxone 0.0% 0.0% 0.0% 3.0% 0.0% 0.0% 0.8% 1.8% 2.6%
(MIC ≥ 64) 0 0 0 3 0 0 2 4 5
Cefoxitin Not Not Not Not 22.3% 25.8% 22.2% 21.3% 15.3%
(MIC ≥ 32) Tested Tested Tested Tested 27 32 53 47 29
Trimethoprim-sulfamethoxazole 3.9% 4.3% 1.3% 2.0% 4.1% 1.6% 4.2% 0.9% 2.1%
(MIC ≥ 4) 2 2 1 2 5 2 10 2 4
Chloramphenicol 5.9% 4.3% 2.6% 18.2% 23.1% 28.2% 24.7% 21.7% 15.3%
(MIC ≥ 32) 3 2 2 18 28 35 59 48 29
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.8% 0.0% 0.5%
(MIC ≥ 32) 0 0 0 0 1 0 2 0 1
Sulfamethoxazole/Sulfisoxazole* 11.8% 4.3% 3.9% 22.2% 23.1% 32.3% 25.1% 24.0% 16.8%
(MIC ≥ 512) 6 2 3 22 28 40 60 53 32
Tetracycline 7.8% 4.3% 2.6% 19.2% 23.1% 30.6% 25.1% 23.5% 16.8%
(MIC ≥ 16) 4 2 2 19 28 38 60 52 32















Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 51 46 77 99 121 124 239 221 190
% % % % % % % % %
n n n n n n n n n
No resistance detected 86.3% 93.5% 94.8% 75.8% 75.2% 65.3% 72.8% 74.2% 82.1%
 44 43 73 75 91 81 174 164 156
Resistance ≥1CLSI subclass* 13.7% 6.5% 5.2% 24.2% 24.8% 34.7% 27.2% 25.8% 17.9%
 7 3 4 24 30 43 65 57 34
Resistance ≥2 CLSI subclasses* 7.8% 4.3% 2.6% 18.2% 23.1% 32.3% 25.1% 24.4% 17.4%
 4 2 2 18 28 40 60 54 33
Resistance ≥3 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 24.7% 22.6% 16.8%
 3 2 2 18 28 39 59 50 32
Resistance ≥4 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 24.7% 22.2% 15.8%
 3 2 2 18 28 39 59 49 30
Resistance ≥5 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 27.4% 23.0% 21.7% 14.7%
 3 2 2 18 28 34 55 48 28
At least ACSSuT† 5.9% 4.3% 1.3% 18.2% 23.1% 25.8% 23.0% 21.3% 14.7%
 3 2 1 18 28 32 55 47 28
At least ACSuTm‡ 3.9% 4.3% 1.3% 2.0% 4.1% 0.8% 3.8% 0.9% 1.1%
 2 2 1 2 5 1 9 2 2
At least ACSSuTAuCf§ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.2% 20.8% 14.7%
 0 0 1 18 27 31 53 46 28
At least MDR-AmpC¶ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.2% 20.8% 14.7%
 0 0 1 18 27 31 53 46 28
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 1.3% 0.0% 0.0% 0.0% 0.4% 0.0% 0.5%
 0 0 1 0 0 0 1 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   




D. Specific Phenotypes 
 
The multidrug-resistant phenotypes ACSSuT and MDR-AmpC, and resistance to nalidixic acid and ceftiofur, were 
detected in several other serotypes in 2004 (Table 1.14). 
 
In 2004, 128 non-Typhi Salmonella isolates were resistant to at least ACSSuT.  Of these isolates, 69.5% were 
serotype Typhimurium, 21.9% Newport, and 0.8% each Agona, Anatum, Enteritidis, Heidelberg, and “monophasic 
Typhimurium.” 
 
Forty-two non-Typhi Salmonella isolates were at least MDR-AmpC.  Of these isolates, 66.7% were serotype 
Newport, 23.8% Typhimurium, 2.4% Agona, and 2.4% Anatum. 
 
Forty-seven non-Typhi Salmonella isolates were nalidixic acid-resistant.  Of these isolates, 38.3% were serotype 
Enteritidis, 4.3% Typhimurium, and 2.1% each Agona, Infantis, Javiana, Montevideo, “monophasic Typhimurium,” 
Newport, and Saintpaul. 
 
Sixty-one non-Typhi Salmonella isolates were ceftiofur-resistant.  Of these isolates, 47.5% were serotype 
Newport, 27.9% Typhimurium, 14.8% Heidelberg, and 1.6% each Agona, Anatum, and monophasic 
Typhimurium.”  
Rank Serotype N n (%) n (%) n (%) n (%)
1 Typhimurium 382 89 (69.5%) 10 (23.8%) 2 (4.3%) 17 (27.9%)
2 Enteritidis 271 1 (0.8%) 0 (0.0%) 18 (38.3%) 0 (0.0%)
3 Newport 190 28 (21.9%) 28 (66.7%) 1 (2.1%) 29 (47.5%)
4 Javiana 106 0 (0.0%) 0 (0.0%) 1 (2.1%) 0 (0.0%)
5 Heidelberg 93 1 (0.8%) 0 (0.0%) 0 (0.0%) 9 (14.8%)
6 Montevideo 50 0 (0.0%) 0 (0.0%) 1 (2.1%) 0 (0.0%)
7 I 4,[5],12:i:- (monophasic Typhimurium) 36 1 (0.8%) 0 (0.0%) 1 (2.1%) 1 (1.6%)
8 Braenderup 33 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
9 Oranienburg 32 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
10 Muenchen 32 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
11 Saintpaul 32 0 (0.0%) 0 (0.0%) 1 (2.1%) 0 (0.0%)
12 Infantis 30 0 (0.0%) 0 (0.0%) 1 (2.1%) 0 (0.0%)
13 Paratyphi B var. L(+) tartrate+ 29 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
14 Thompson 26 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
15 Mississippi 24 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
16 Agona 24 1 (0.8%) 1 (2.4%) 1 (2.1%) 1 (1.6%)
17 Hartford 18 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
18 Anatum 16 1 (0.8%) 1 (2.4%) 0 (0.0%) 1 (1.6%)
19 Berta 14 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
20 Mbandaka 14 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Subtotal 1452 122 (95.3%) 40 (95.2%) 27 (57.4%) 58 (95.1%)
All Other Serotypes 341 6 (4.7%) 2 (4.8%) 20 (42.6%) 3 (4.9%)
Total 1793 128 (100.0%) 42 (100.0%) 47 (100.0%) 61 (100.0%)
*ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
† MDR-AmpC: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur + decreased susceptibility to 
ceftriaxone (MIC ≥2µg/mL)
Table 1.14: Number and percentage of ACSSuT-, MDR-AmpC-, nalidixic acid-, and ceftiofur-resistant 
isolates among the 20 most common non-Typhi Salmonella  serotypes isolated in NARMS, 2004















Extended-spectrum cephalosporins are important for treating persons with severe Salmonella infections 
[Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001;32:263–9]. This drug class is particularly 
important for pediatric therapy because fluoroquinolones are not approved for use in children. In 2004, 34% 
(11,976/35,661) of laboratory-confirmed Salmonella cases reported to CDC occurred in children <10 years of age 
[CDC. PHLIS Salmonella 2004 Annual Summary. Division of Bacterial and Mycotic Diseases. 2005. Available at 
http://www.cdc.gov/ncidod/dbmd/phlisdata/salmtab/2004/SalmonellaTable2_2004.pdf]. NARMS conducts 
surveillance for resistance to two extended-spectrum cephalosporins: ceftriaxone (approved for use in humans) 
and ceftiofur (approved for use in food animals). The prevalence of resistance to ceftiofur among non-Typhi 
Salmonella isolates tested in NARMS increased from 1996 to 2004 (Figure 1.1). 
 
To facilitate an understanding of this increase in resistance, isolates that exhibited a ceftriaxone minimum 
inhibitory concentration (MIC) of ≥2 µg/mL or a ceftiofur MIC of ≥2 µg/mL also were tested for extended-spectrum 
cephalosporin-resistance mechanisms. Of the 2629 non-Typhi Salmonella and Shigella isolates tested in 2002, 
95 (3.6%) isolates, including 94 Salmonella and one Shigella, met these criteria for additional testing. This 
included susceptibility testing of additional β-lactams, such as ceftazidime and cefotaxime, and molecular 
characterization of β-lactamases and β-lactamase genes. Ninety-two percent (87/95) of the isolates exhibited a 
ceftazidime or cefotaxime MIC that was intermediate or resistant; 76% (72/95) exhibited a ceftazidime or 
cefotaxime MIC that was resistant. 
  
Isoelectric focusing was performed for β-lactamases and polymerase chain reaction (PCR) for blaCMY, blaSHV and 
blaTEM genes. Of the 95 isolates, 93 (92 Salmonella and one Shigella) were positive by isoelectric focusing for one 
or more β-lactams. Of the 92 Salmonella isolates with one or more β-lactams, 53 (58%) were Salmonella 
Newport; 19 (21%) were Salmonella Typhimurium; and eight (9%) were Salmonella Heidelberg; six (7%) isolates 
were cultured from blood. Among these 92 isolates, 86 (93%) were positive by PCR for a CMY mechanism, 12 
(13%) were positive for a TEM mechanism, and one (1%) was positive for a SHV mechanism. Ten (11%) isolates 




Figure 1.1: Prevalence of resistance to ceftiofur 
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2. SALMONELLA TYPHI 
 
In 2004, CDC received 349 Salmonella Typhi isolates, of which 341 (97.7%) were viable and tested for 
antimicrobial susceptibility.  Of these 341 isolates, 37 isolates were excluded from the analysis because they were 
submissions from the same patient, leaving 304 isolates for analysis (Table I).  Antimicrobial agents with the 
highest prevalence of resistance were nalidixic acid (41.8%), trimethoprim-sulfamethoxazole (13.2%), 
chloramphenicol (13.2%), ampicillin (11.8%), streptomycin (11.8%), and sulfisoxazole (11.8%). 
 
Resistance decreased from 2003 to 2004 to most of the antimicrobial agents tested (Table 2.2). However, 
nalidixic acid resistance increased from 18.7% in 1999 to 41.8% in 2004; a statistically significant increase 
(OR=3.1, 95% CI [1.9, 4.9]). 
 
In 1999, 12.0% of Salmonella Typhi isolates were resistant to at least ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole (ACSuTm), which increased to 15.6% in 2003 but declined to 11.8% in 2004 
(Table 2.3). 
 
Table 2.1: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Typhi isolates to antimicrobial agents, 2004 (N=304)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.2] 28.0 68.4 3.6
Gentamicin 0.0 0.0 [0.0–1.2] 96.1 3.9
Kanamycin 0.0 0.0 [0.0–1.2] 100.0
Streptomycin NA 11.8 [8.4–16.0] 88.2 0.3 11.5
Aminopenicillins Ampicillin 0.0 11.8 [8.4–16.0] 72.4 15.8 11.8
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.3 0.0 [0.0–1.2] 87.5 0.7 3.9 7.6 0.3
Ceftiofur 0.0 0.0 [0.0–1.2] 2.3 18.8 75.0 3.9
Ceftriaxone 0.0 0.0 [0.0–1.2] 100.0
Cephamycins Cefoxitin 0.7 0.0 [0.0–1.2] 3.9 45.4 9.9 28.0 12.2 0.7
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 13.2 [9.6–17.5] 77.3 9.5 13.2
Phenicols Chloramphenicol 0.0 13.2 [9.6–17.5] 3.3 74.3 9.2 13.2
Ciprofloxacin 0.0 0.0 [0.0–1.2] 53.6 0.3 3.6 15.1 26.0 1.3
Nalidixic Acid NA 41.8 [36.2–47.5] 1.3 50.0 3.6 3.3 1.0 40.8
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 11.8 [8.4–16.0] 53.6 30.6 3.6 0.3 11.8
Tetracyclines Tetracycline 0.0 8.9 [5.9–12.7] 91.1 8.9
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides





Year 1999 2000 2001 2002 2003 2004




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 0 0
Kanamycin 0.0% 0.0% 0.5% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 0 0 0
Streptomycin 13.3% 9.0% 20.3% 7.2% 14.4% 11.8%
(MIC ≥ 64) 22 16 40 14 48 36
Ampicillin 12.7% 9.0% 20.3% 5.6% 16.2% 11.8%
(MIC ≥ 32) 21 16 40 11 54 36
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.0% 0.3% 0.0%
(MIC ≥ 32) 1 0 0 0 1 0
Cephalothin 2.4% 1.1% 0.5% 1.5% 0.6% Not
(MIC ≥ 32) 4 2 1 3 2 Tested
Ceftiofur 0.6% 0.0% 0.0% 0.0% 0.6% 0.0%
(MIC ≥ 8) 1 0 0 0 2 0
Ceftriaxone 0.6% 0.0% 0.0% 0.0% 0.3% 0.0%
(MIC ≥ 64) 1 0 0 0 1 0
Cefoxitin Not 0.6% 0.5% 0.0% 0.9% 0.0%
(MIC ≥ 32) Tested 1 1 0 3 0
Trimethoprim-sulfamethoxazole 12.7% 9.0% 20.8% 6.7% 16.8% 13.2%
(MIC ≥ 4) 21 16 41 13 56 40
Chloramphenicol 12.0% 10.7% 20.8% 6.2% 16.5% 13.2%
(MIC ≥ 32) 20 19 41 12 55 40
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.3% 0.0%
(MIC ≥ 4) 0 0 0 0 1 0
Nalidixic Acid 18.7% 22.0% 29.9% 23.6% 37.7% 41.8%
(MIC ≥ 32) 31 39 59 46 126 127
Sulfamethoxazole/Sulfisoxazole* 16.3% 11.3% 20.8% 6.2% 17.1% 11.8%
(MIC ≥ 512) 27 20 41 12 57 36
Tetracycline 9.0% 9.6% 20.8% 6.7% 15.6% 8.9%
(MIC ≥ 16) 15 17 41 13 52 27


















Year 1999 2000 2001 2002 2003 2004
Total Isolates 166 177 197 195 334 304
% % % % % %
n n n n n n
No resistance detected 71.7% 72.9% 59.4% 74.4% 56.6% 56.6%
 119 129 117 145 189 172
Resistance ≥1CLSI subclass* 28.3% 27.1% 40.6% 25.6% 43.4% 43.4%
 47 48 80 50 145 132
Resistance ≥2 CLSI subclasses* 14.5% 10.7% 22.8% 7.2% 18.0% 13.2%
 24 19 45 14 60 40
Resistance ≥3 CLSI subclasses* 12.7% 9.6% 22.8% 6.7% 17.7% 12.8%
 21 17 45 13 59 39
Resistance ≥4 CLSI subclasses* 12.7% 9.0% 21.8% 6.7% 16.8% 12.5%
 21 16 43 13 56 38
Resistance ≥5 CLSI subclasses* 12.0% 9.0% 18.8% 5.6% 15.9% 11.8%
 20 16 37 11 53 36
At least ACSSuT† 9.0% 7.9% 16.8% 5.6% 12.6% 7.9%
 15 14 33 11 42 24
At least ACSuTm‡ 12.0% 9.0% 17.8% 5.6% 15.6% 11.8%
 20 16 35 11 52 36
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.3% 0.0%
 0 0 0 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   






























In 2004, CDC received 367 Shigella isolates, of which 320 (87.2%) were viable and tested for antimicrobial 
susceptibility.  Of these 320 isolates, three submissions from the same patient and two isolates identified as not 
Shigella were excluded, leaving 315 isolates for analysis.  (Table I). Of the 315 isolates tested, 241 (76.5%) were 
S. sonnei; 61 (19.4%), S. flexneri; nine (2.9%), S. boydii; and two (0.6%), S. dysenteriae (Table 3.1). Resistance 
was highest to ampicillin (77.8%), streptomycin (61.0%), sulfisoxazole (52.4%), trimethoprim-sulfamethoxazole 
(51.4%), and tetracycline (49.2%) (Table 3.2). 
 
Shigella flexneri isolates showed a higher prevalence of resistance to most antimicrobial agents than did Shigella 
sonnei (Tables 3.3 and 3.4). Important differences between the species include the prevalence of tetracycline 
resistance (95.1% in S. flexneri, compared with 36.1% in S. sonnei) and chloramphenicol resistance (60.7% in S. 
flexneri, compared with 2.5% in S. sonnei). 
 
The percentage of S. sonnei isolates resistant to trimethoprim-sulfamethoxazole increased from 38.5% in 2003 to 
53.1% in 2004 (Table 3.6), a rate similar to that during 1999–2000 (53.1–54.9%). Ampicillin resistance among S. 
sonnei isolates remained high (79.3%). Tetracycline resistance also increased from 22.1% in 2003 to 36.1% in 
2004. One S. sonnei isolate was resistant to ceftriaxone; this is the first ceftriaxone-resistant Shigella isolate 
detected since NARMS began testing Shigella in 1999. 
 
Resistance of S. flexneri isolates to trimethoprim-sulfamethoxazole also apparently increased from the low of 
28.8% in 2002 to 45.9% in 2004 (Table 3.7). However, nalidixic acid resistance was 1.6% in 2004, compared with 
5.9% in 2003. Resistance to streptomycin and tetracycline was higher in 2004 (72.1% and 95.1%, respectively) 
than during 1999–2003. In 2004, chloramphenicol resistance among S. flexneri isolates was the lowest of the 6-
year period (60.7%). 
 
In all years from 1999 to 2004, more than 90% of Shigella isolates tested were resistant to at least one CLSI 
subclass. A total of 40.5% were resistant to at least five subclasses in 1999, compared with 27.6% in 2004 (Table 
3.8). 
 
For both S. sonnei and S. flexneri, resistance to multiple antimicrobial classes and specific combinations changed 
from 1999 to 2004 (Tables 3.9 and 3.10). One Shigella (S. sonnei) isolate was resistant to nalidixic acid and 
ceftiofur. This is the first S. sonnei isolate with this phenotype reported in NARMS. The first reported Shigella 
isolate with this phenotype in NARMS was a S. flexneri isolated in 2003. The nalidixic acid- and ceftiofur-resistant 
S. sonnei isolate is also the first ceftriaxone-resistant Shigella isolate reported in NARMS. Combined resistance to 
ampicillin and trimethoprim-sulfamethoxazole (ASuTm) was present in more than 40% of isolates from 1999 
through 2001, declined to 30.2% in 2002, but increased to 33.6% in 2003 and 39.4% in 2004. Resistance to both 




Shigella sonnei 241 (76.5%)
Shigella flexneri 61 (19.4%)
Shigella boydii 9 (2.9%)




Table 3.1: Frequency of Shigella 













Table 3.2: Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial agents, 2004 (N=316)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.2] 4.1 54.9 37.8 2.9 0.3
Gentamicin 0.0 0.0 [0.0–1.2] 1.9 44.8 51.7 1.6
Kanamycin 0.0 0.0 [0.0–1.2] 100.0
Streptomycin NA 61.0 [55.3–66.4] 39.0 20.3 40.6
Aminopenicillins Ampicillin 0.3 77.8 [72.8–82.2] 3.8 9.8 6.0 2.2 0.3 0.6 77.1
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 24.8 1.6 [0.5–3.7] 0.6 3.8 16.8 52.4 24.8 1.0 0.6
Ceftiofur 0.0 0.3 [0.0–1.8] 34.9 59.7 4.8 0.3 0.3
Ceftriaxone 0.0 0.3 [0.0–1.8] 99.4 0.3 0.3
Cephamycins Cefoxitin 0.3 0.3 [0.0–1.8] 0.3 10.8 67.0 19.7 1.6 0.3 0.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 51.4 [45.8–57.1] 32.4 10.2 2.2 1.9 1.9 2.5 48.9
Phenicols Chloramphenicol 4.4 14.9 [11.2–19.3] 11.1 63.5 6.0 4.4 2.2 12.7
Ciprofloxacin 0.0 0.0 [0.0–1.2] 98.1 0.3 0.6 1.0
Nalidixic Acid NA 1.6 [0.5–3.7] 0.3 60.6 35.9 1.6 0.6 1.0
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 52.4 [46.7–58.0] 44.4 3.2 52.4
Tetracyclines Tetracycline 0.3 49.2 [43.6–54.9] 50.5 0.3 9.5 39.7
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides





Table 3.3: Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to antimicrobial agents, 2004 (N=241)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.5] 4.6 62.7 30.7 2.1
Gentamicin 0.0 0.0 [0.0–1.5] 2.1 47.7 48.5 1.7
Kanamycin 0.0 0.0 [0.0–1.5] 100.0
Streptomycin NA 58.1 [51.6–64.4] 41.9 21.2 36.9
Aminopenicillins Ampicillin 0.4 79.3 [73.6–84.2] 0.8 10.4 6.2 2.9 0.4 0.8 78.4
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 16.6 1.7 [0.5–4.2] 0.4 1.2 17.0 63.1 16.6 0.8 0.8
Ceftiofur 0.0 0.4 [0.0–2.3] 27.4 66.4 5.4 0.4 0.4
Ceftriaxone 0.0 0.4 [0.0–2.3] 99.2 0.4 0.4
Cephamycins Cefoxitin 0.4 0.4 [0.0–2.3] 0.4 12.9 73.0 12.0 0.8 0.4 0.4
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 53.1 [46.6–59.5] 33.2 7.9 1.7 2.1 2.1 3.3 49.8
Phenicols Chloramphenicol 5.4 2.5 [0.9–5.3] 3.3 81.3 7.5 5.4 0.4 2.1
Ciprofloxacin 0.0 0.0 [0.0–1.5] 98.3 0.8 0.8
Nalidixic Acid NA 1.7 [0.5–4.2] 0.4 60.6 35.7 1.7 0.8 0.8
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 49.0 [42.5–55.5] 46.9 4.1 49.0
Tetracyclines Tetracycline 0.4 36.1 [30.0–42.5] 63.5 0.4 8.3 27.8
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides










Table 3.4: Minimum inhibitory concentrations (MICs) and resistance of Shilgella flexneri isolates to antimicrobial agents, 2004 (N=61)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–5.9] 3.3 27.9 60.7 6.6 1.6
Gentamicin 0.0 0.0 [0.0–5.9] 1.6 36.1 60.7 1.6
Kanamycin 0.0 0.0 [0.0–5.9] 100.0
Streptomycin NA 72.1 [59.2–82.9] 27.9 19.7 52.5
Aminopenicillins Ampicillin 0.0 82.0 [70.0–90.6] 14.8 1.6 1.6 82.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 55.7 1.6 [0.0–8.8] 1.6 13.1 6.6 21.3 55.7 1.6
Ceftiofur 0.0 0.0 [0.0–5.9] 55.7 41.0 3.3
Ceftriaxone 0.0 0.0 [0.0–5.9] 100.0
Cephamycins Cefoxitin 0.0 0.0 [0.0–5.9] 1.6 45.9 49.2 3.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 45.9 [33.1–59.2] 31.1 16.4 4.9 1.6 45.9
Phenicols Chloramphenicol 1.6 60.7 [47.3–72.9] 34.4 3.3 1.6 8.2 52.5
Ciprofloxacin 0.0 0.0 [0.0–5.9] 96.7 1.6 1.6
Nalidixic Acid NA 1.6 [0.0–8.8] 60.7 36.1 1.6 1.6
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 65.6 [52.3–77.3] 34.4 65.6
Tetracyclines Tetracycline 0.0 95.1 [86.3–99.0] 4.9 13.1 82.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides






Year 1999 2000 2001 2002 2003 2004




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0
Gentamicin 0.3% 0.2% 0.0% 0.2% 0.0% 0.0%
(MIC ≥ 16) 1 1 0 1 0 0
Kanamycin 0.5% 1.3% 0.6% 0.8% 0.4% 0.0%
(MIC ≥ 64) 2 6 2 5 2 0
Streptomycin 55.7% 57.1% 53.2% 54.4% 57.0% 61.0%
(MIC ≥ 64) 209 257 183 337 282 192
Ampicillin 77.6% 79.1% 79.7% 76.6% 79.4% 77.8%
(MIC ≥ 32) 291 356 274 475 393 245
Amoxicillin-clavulanic acid 1.1% 2.2% 4.4% 2.6% 1.4% 1.6%
(MIC ≥ 32) 4 10 15 16 7 5
Cephalothin 3.2% 8.0% 9.0% 6.6% 9.3% Not
(MIC ≥ 32) 12 36 31 41 46 Tested
Ceftiofur 0.0% 0.0% 0.0% 0.2% 0.2% 0.3%
(MIC ≥ 8) 0 0 0 1 1 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.3%
(MIC ≥ 64) 0 0 0 0 0 1
Cefoxitin Not 0.2% 1.2% 0.3% 0.0% 0.3%
(MIC ≥ 32) Tested 1 4 2 0 1
Trimethoprim-sulfamethoxazole 51.5% 52.9% 46.8% 37.3% 38.6% 51.4%
(MIC ≥ 4) 193 238 161 231 191 162
Chloramphenicol 17.3% 14.0% 21.5% 7.6% 8.5% 14.9%
(MIC ≥ 32) 65 63 74 47 42 47
Ciprofloxacin 0.0% 0.0% 0.3% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 1 0 0 0
Nalidixic Acid 1.6% 0.9% 1.7% 1.6% 1.0% 1.6%
(MIC ≥ 32) 6 4 6 10 5 5
Sulfamethoxazole/Sulfisoxazole* 56.0% 55.8% 56.4% 31.8% 33.9% 52.4%
(MIC ≥ 512) 210 251 194 197 168 165
Tetracycline 57.3% 44.9% 59.3% 30.6% 29.1% 49.2%
(MIC ≥ 16) 215 202 204 190 144 155
*Sulfamethoxazole, which was tested during 1999-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
Aminopenicillins
β-lactamase inhibitor combinations













Year 1999 2000 2001 2002 2003 2004




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0
Gentamicin 0.4% 0.3% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 1 1 0 0 0 0
Kanamycin 0.7% 1.6% 0.4% 0.4% 0.0% 0.0%
(MIC ≥ 64) 2 6 1 2 0 0
Streptomycin 52.0% 56.0% 54.0% 55.4% 56.5% 58.1%
(MIC ≥ 64) 143 205 129 297 245 140
Ampicillin 79.6% 80.6% 82.8% 77.6% 79.7% 79.3%
(MIC ≥ 32) 219 295 198 416 346 191
Amoxicillin-clavulanic acid 0.4% 1.9% 4.6% 2.2% 1.4% 1.7%
(MIC ≥ 32) 1 7 11 12 6 4
Cephalothin 2.9% 8.7% 12.6% 7.3% 10.1% Not
(MIC ≥ 32) 8 32 30 39 44 Tested
Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 0.4%
(MIC ≥ 8) 0 0 0 0 0 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.4%
(MIC ≥ 64) 0 0 0 0 0 1
Cefoxitin Not 0.3% 1.7% 0.4% 0.0% 0.4%
(MIC ≥ 32) Tested 1 4 2 0 1
Trimethoprim-sulfamethoxazole 53.1% 54.9% 50.6% 37.9% 38.5% 53.1%
(MIC ≥ 4) 146 201 121 203 167 128
Chloramphenicol 1.8% 2.7% 1.3% 0.2% 1.2% 2.5%
(MIC ≥ 32) 5 10 3 1 5 6
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0
Nalidixic Acid 1.5% 1.1% 0.8% 1.5% 0.5% 1.7%
(MIC ≥ 32) 4 4 2 8 2 4
Sulfamethoxazole/Sulfisoxazole* 54.5% 56.0% 54.4% 29.9% 31.3% 49.0%
(MIC ≥ 512) 150 205 130 160 136 118
Tetracycline 46.2% 34.4% 44.8% 23.5% 22.1% 36.1%
(MIC ≥ 16) 127 126 107 126 96 87
*Sulfamethoxazole, which was tested during 1999-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
Aminopenicillins
β-lactamase inhibitor combinations













Year 1999 2000 2001 2002 2003 2004




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 1.4% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 1 0 0
Kanamycin 0.0% 0.0% 1.1% 4.1% 3.9% 0.0%
(MIC ≥ 64) 0 0 1 3 2 0
Streptomycin 63.2% 61.3% 47.3% 43.8% 60.8% 72.1%
(MIC ≥ 64) 55 46 43 32 31 44
Ampicillin 77.0% 77.3% 72.5% 75.3% 84.3% 82.0%
(MIC ≥ 32) 67 58 66 55 43 50
Amoxicillin-clavulanic acid 3.4% 4.0% 4.4% 5.5% 2.0% 1.6%
(MIC ≥ 32) 3 3 4 4 1 1
Cephalothin 4.6% 2.7% 1.1% 2.7% 3.9% Not
(MIC ≥ 32) 4 2 1 2 2 Tested
Ceftiofur 0.0% 0.0% 0.0% 1.4% 2.0% 0.0%
(MIC ≥ 8) 0 0 0 1 1 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0
Cefoxitin Not 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested 0 0 0 0 0
Trimethoprim-sulfamethoxazole 48.3% 42.7% 34.1% 28.8% 39.2% 45.9%
(MIC ≥ 4) 42 32 31 21 20 28
Chloramphenicol 64.4% 69.3% 74.7% 63.0% 68.6% 60.7%
(MIC ≥ 32) 56 52 68 46 35 37
Ciprofloxacin 0.0% 0.0% 1.1% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 1 0 0 0
Nalidixic Acid 1.1% 0.0% 3.3% 2.7% 5.9% 1.6%
(MIC ≥ 32) 1 0 3 2 3 1
Sulfamethoxazole/Sulfisoxazole* 58.6% 53.3% 57.1% 41.1% 52.9% 65.6%
(MIC ≥ 512) 51 40 52 30 27 40
Tetracycline 92.0% 92.0% 94.5% 78.1% 82.4% 95.1%
(MIC ≥ 16) 80 69 86 57 42 58
*Sulfamethoxazole, which was tested during 1999-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
Aminopenicillins
β-lactamase inhibitor combinations












Year 1999 2000 2001 2002 2003 2004
Total Isolates 375 450 344 620 495 315
% % % % % %
n n n n n n
No resistance detected 9.1% 7.3% 4.9% 8.2% 8.5% 4.4%
 34 33 17 51 42 14
Resistance ≥1CLSI subclass* 90.9% 92.7% 95.1% 91.8% 91.5% 95.6%
 341 417 327 569 453 301
Resistance ≥2 CLSI subclasses* 63.7% 64.7% 69.8% 55.3% 57.8% 66.7%
 239 291 240 343 286 210
Resistance ≥3 CLSI subclasses* 61.1% 62.0% 61.3% 41.8% 41.4% 62.2%
 229 279 211 259 205 196
Resistance ≥4 CLSI subclasses* 54.1% 56.7% 54.1% 31.0% 32.5% 52.1%
 203 255 186 192 161 164
Resistance ≥5 CLSI subclasses* 40.5% 26.2% 36.0% 20.5% 22.4% 27.6%
 152 118 124 127 111 87
At least ACSSuT† 8.5% 5.6% 6.4% 1.8% 3.2% 6.0%
 32 25 22 11 16 19
At least ACSuTm‡ 9.9% 6.9% 7.0% 2.7% 3.6% 6.7%
 37 31 24 17 18 21
At least ASuTm§ 44.3% 44.4% 37.5% 29.8% 33.7% 37.8%
 166 200 129 185 167 119
At least ANSuTm¶ 0.3% 0.0% 0.6% 0.3% 0.8% 0.6%
 1 0 2 2 4 2
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.2% 0.3%
 0 0 0 0 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  





Year 1999 2000 2001 2002 2003 2004
Total Isolates 275 366 239 536 434 241
% % % % % %
n n n n n n
No resistance detected 10.5% 7.7% 5.4% 7.1% 8.5% 5.0%
 29 28 13 38 37 12
Resistance ≥1CLSI subclass* 89.5% 92.3% 94.6% 92.9% 91.5% 95.0%
 246 338 226 498 397 229
Resistance ≥2 CLSI subclasses* 56.0% 60.7% 60.7% 52.1% 54.1% 59.8%
 154 222 145 279 235 144
Resistance ≥3 CLSI subclasses* 54.5% 57.7% 53.1% 36.6% 36.2% 54.4%
 150 211 127 196 157 131
Resistance ≥4 CLSI subclasses* 50.5% 54.1% 49.0% 26.7% 28.6% 46.5%
 139 198 117 143 124 112
Resistance ≥5 CLSI subclasses* 38.5% 23.5% 36.0% 19.4% 20.0% 24.9%
 106 86 86 104 87 60
At least ACSSuT† 0.4% 0.8% 0.0% 0.0% 0.2% 0.0%
 1 3 0 0 1 0
At least ACSuTm‡ 1.8% 1.9% 0.8% 0.2% 0.9% 1.7%
 5 7 2 1 4 4
At least ASuTm§ 45.1% 46.2% 41.0% 30.2% 33.6% 39.4%
 124 169 98 162 146 95
At least ANSuTm¶ 0.0% 0.0% 0.0% 0.2% 0.2% 0.8%
 0 0 0 1 1 2
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.4%
 0 0 0 0 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  





Year 1999 2000 2001 2002 2003 2004
Total Isolates 87 75 91 73 51 61
% % % % % %
n n n n n n
No resistance detected 4.6% 4.0% 3.3% 15.1% 7.8% 0.0%
 4 3 3 11 4 0
Resistance ≥1CLSI subclass* 95.4% 96.0% 96.7% 84.9% 92.2% 100.0%
 83 72 88 62 47 61
Resistance ≥2 CLSI subclasses* 83.9% 82.7% 90.1% 76.7% 86.3% 93.4%
 73 62 82 56 44 57
Resistance ≥3 CLSI subclasses* 80.5% 81.3% 80.2% 75.3% 82.4% 91.8%
 70 61 73 55 42 56
Resistance ≥4 CLSI subclasses* 67.8% 69.3% 65.9% 58.9% 64.7% 75.4%
 59 52 60 43 33 46
Resistance ≥5 CLSI subclasses* 49.4% 40.0% 31.9% 28.8% 45.1% 41.0%
 43 30 29 21 23 25
At least ACSSuT† 33.3% 29.3% 22.0% 15.1% 29.4% 27.9%
 29 22 20 11 15 17
At least ACSuTm‡ 34.5% 32.0% 23.1% 21.9% 27.5% 24.6%
 30 24 21 16 14 15
At least ASuTm§ 44.8% 38.7% 25.3% 27.4% 37.3% 36.1%
 39 29 23 20 19 22
At least ANSuTm¶ 1.1% 0.0% 1.1% 1.4% 5.9% 0.0%
 1 0 1 1 3 0
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 2.0% 0.0%
 0 0 0 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  





















4. ESCHERICHIA COLI O157 
 
In 2004, CDC received a total of 177 Escherichia coli O157 isolates, of which 170 (96.0%) were viable and tested 
for antimicrobial susceptibility.  Of these 170 isolates, one isolate was excluded from the analysis because it was 
a duplicate submission, leaving 169 isolates for analysis (Table I).  Antimicrobial agents with the highest 
prevalence of resistance were nalidixic acid (1.8%), sulfisoxazole (1.8%), streptomycin (1.8%), and tetracycline 
(1.8%) (Table 4.2). Ampicillin resistance decreased from 3.2% in 2003 to 1.2% in 2004 (Table 4.2). Cefoxitin and 
chloramphenicol resistance decreased to 0.6% in 2004, down from 1.3% in 2003. No isolates in 2004 were 
resistant to ceftiofur, whereas two isolates were resistant in 2003 (Table 4.2). 
 
Isolates resistant to at least one CLSI subclass decreased from 9.6% in 2003 to 4.7% in 2004 (Table 4.3). 
Resistance to at least two CLSI subclasses decreased from 5.1% in 2003 to 1.2% in 2004. No isolates were 
resistant to at least five subclasses in 2004, but one (0.6%) was resistant in 2003. 
 
Antimicrobial treatment of E. coli O157 infections is not recommended, but resistance changes, particularly 
appearance of third-generation cephalosporin resistance, might prove useful in understanding exchange of mobile 
resistance elements in bovine production settings. 
 
Table 4.1: Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to antimicrobial agents, 2004 (N=169)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–2.2] 5.9 68.0 22.5 3.6
Gentamicin 0.0 0.6 [0.0–3.3] 57.4 37.3 4.7 0.6
Kanamycin 0.0 0.0 [0.0–2.2] 100.0
Streptomycin NA 1.8 [0.4–5.1] 98.2 0.6 1.2
Aminopenicillins Ampicillin 0.0 1.2 [0.1–4.2] 5.3 59.2 31.4 3.0 1.2
β-lactamase 
inhibitor 
Amoxicillin-clavulanic acid 0.6 0.0 [0.0–2.2] 3.6 6.5 88.2 1.2 0.6
Ceftiofur 0.0 0.0 [0.0–2.2] 2.4 43.2 52.1 2.4
Ceftriaxone 0.0 0.0 [0.0–2.2] 100.0
Cephamycins Cefoxitin 1.2 0.6 [0.0–3.3] 0.6 3.0 5.9 70.4 18.3 1.2 0.6
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.0 [0.0–2.2] 94.1 5.9
Phenicols Chloramphenicol 0.6 0.6 [0.0–3.3] 1.8 46.2 50.9 0.6 0.6
Ciprofloxacin 0.0 0.0 [0.0–2.2] 97.6 0.6 0.6 1.2
Nalidixic Acid NA 1.8 [0.4–5.1] 2.4 75.7 19.5 0.6 1.8
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 1.8 [0.4–5.1] 92.9 5.3 1.8
Tetracyclines Tetracycline 0.0 1.8 [0.4–5.1] 98.2 0.6 1.2
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations 
represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides






Year 1996 1997 1998 1999 2000 2001 2002 2003 2004




Aminoglycosides Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.3% 0.5% 0.4% 0.0% 0.0% 0.6%
(MIC ≥ 16) 0 0 0 1 2 1 0 0 1
Kanamycin 0.0% 0.0% 0.3% 0.7% 1.0% 0.0% 0.5% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 2 4 0 2 0 0
Streptomycin 2.0% 2.5% 1.9% 2.7% 5.2% 1.8% 2.3% 1.9% 1.8%
(MIC ≥ 64) 4 4 6 8 21 5 9 3 3
Aminopenicillins Ampicillin 1.5% 0.0% 2.5% 1.4% 2.7% 2.2% 1.5% 3.2% 1.2%
(MIC ≥ 32) 3 0 8 4 11 6 6 5 2
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.3% 1.0% 0.7% 0.0% 1.3% 0.0%
(MIC ≥ 32) 0 0 0 1 4 2 0 2 0
Cephalothin 1.5% 2.5% 0.0% 0.7% 1.2% 1.4% 1.5% 2.5% Not
(MIC ≥ 32) 3 4 0 2 5 4 6 4 Teste
Ceftiofur 0.0% 0.0% 0.0% 0.0% 1.0% 1.1% 0.0% 1.3% 0.0%
(MIC ≥ 8) 0 0 0 0 4 3 0 2 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0
Cephamycins Cefoxitin Not Not Not Not 1.0% 0.7% 0.0% 1.3% 0.6%
(MIC ≥ 32) Tested Tested Tested Tested 4 2 0 2 1
Folate pathway inhibitors Trimethoprim-sulfamethoxazole 0.0% 0.0% 0.6% 1.4% 0.7% 0.7% 0.5% 0.6% 0.0%
(MIC ≥ 4) 0 0 2 4 3 2 2 1 0
Phenicols Chloramphenicol 0.5% 0.0% 0.3% 0.0% 3.7% 1.4% 1.3% 1.3% 0.6%
(MIC ≥ 32) 1 0 1 0 15 4 5 2 1
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.0% 0.7% 0.5% 1.1% 1.0% 0.6% 1.8%
(MIC ≥ 32) 0 0 0 2 2 3 4 1 3
Sulfonamides Sulfamethoxazole/Sulfisoxazole* 11.9% 9.9% 5.7% 8.2% 5.9% 5.1% 3.5% 3.8% 1.8%
(MIC ≥ 512) 24 16 18 24 24 14 14 6 3
Tetracyclines Tetracycline 5.0% 3.1% 4.4% 3.4% 7.1% 5.4% 3.0% 5.7% 1.8%
(MIC ≥ 16) 10 5 14 10 29 15 12 9 3
*Sulfamethoxazole, which was tested during 1996-2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004.






Year 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 201 161 318 292 407 277 399 157 169
% % % % % % % % %
n n n n n n n n n
No resistance detected 86.6% 88.8% 92.8% 89.7% 90.4% 91.3% 94.0% 90.4% 95.3%
 174 143 295 262 368 253 375 142 161
Resistance ≥1CLSI subclass* 13.4% 11.2% 7.2% 10.3% 9.6% 8.7% 6.0% 9.6% 4.7%
 27 18 23 30 39 24 24 15 8
Resistance ≥2 CLSI subclasses* 5.0% 3.7% 5.3% 3.4% 6.6% 5.4% 3.8% 5.1% 1.2%
 10 6 17 10 27 15 15 8 2
Resistance ≥3 CLSI subclasses* 1.5% 0.6% 1.9% 3.1% 4.7% 2.2% 2.0% 3.2% 0.6%
 3 1 6 9 19 6 8 5 1
Resistance ≥4 CLSI subclasses* 0.5% 0.0% 0.9% 1.0% 3.7% 1.8% 1.0% 1.3% 0.6%
 1 0 3 3 15 5 4 2 1
Resistance ≥5 CLSI subclasses* 0.5% 0.0% 0.0% 0.7% 1.5% 0.7% 0.3% 0.6% 0.0%
 1 0 0 2 6 2 1 1 0
At least ACSSuT† 0.5% 0.0% 0.0% 0.0% 1.2% 0.4% 0.0% 0.0% 0.0%
 1 0 0 0 5 1 0 0 0
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 0 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   





In 2004, CDC received 449 Campylobacter isolates, of which 431 isolates (95.9%) were viable and tested for 
antimicrobial susceptibility.  Of these 431 isolates, 70 isolates that were not part of the sampling scheme, eight 
isolates that were not Campylobacter, and six submissions from patients residing outside the catchment area 
were excluded, leaving 347 isolates for analysis (Table I). A total of 320 (92.2%) were C. jejuni and 26 (7.5%) 
were C. coli (Table 5.1). 
 
For the Campylobacter isolates tested in 2004, resistance was highest to tetracycline (46.1%), nalidixic acid 
(19.6%), and ciprofloxacin (19.0%) (Table 5.3).  Of these isolates tested, 1.4% were resistant to chloramphenicol. 
 
The percentage of Campylobacter isolates resistant to ciprofloxacin increased from 12.9% in 1997 and peaked at 
20.1% in 2002 (Table 5.3).  (This significant increase was reported in previous annual reports.)  The percentage 
of Campylobacter isolates resistant to ciprofloxacin was 19.0% in 2004, which is not a statistically significant 
increase from 1997 (OR=1.6, 95% CI [1.0, 2.6]).  Resistance to erythromycin remained low at 0.3% in 2004. 
 
In 2004, 53.9% of Campylobacter isolates were resistant to one or more CLSI subclass, compared with 48.8% in 
2003 (Table 5.4). In 2004, 14.1% of Campylobacter isolates were resistant to two or more subclasses, compared 
with 8.5% in 2003. 
 
The antimicrobial agent with the highest prevalence of resistance among the 320 C. jejuni isolates was tetracycline 
(46.9%), followed by nalidixic acid (18.4%) and ciprofloxacin (18.1%) (Table 5.6). Of note, 0.3% and 1.6% of C. 
jejuni isolates were resistant to gentamicin and chloramphenicol, respectively. 
 
The percentage of C. jejuni isolates resistant to ciprofloxacin increased from 12.4% in 1997 to 18.1% in 2004 
(Table 5.6), but the increase was not statistically significant (OR=1.6, 95% CI [0.9, 2.6]). Resistance to 
erythromycin remained low at 0.3% in 2004. 
 
The highest levels of resistance among the 26 C. coli isolates were to tetracycline (38.5%), nalidixic acid (34.6%), 
and ciprofloxacin (30.8%) (Table 5.8). The percentage of C. coli isolates resistant to ciprofloxacin was 33.3% in 
1997 and 30.8% in 2004 (Table 5.8). Resistance to erythromycin, which was 12.5% in 1998 and 4.0%–10.0% 
during 1999–2003, was not detected in 2004. 
 
N (%)
Campylobacter jejuni 320 (92.2%)




Table 5.1: Frequency of 




















Table 5.2: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter isolates to antimicrobial agents, 2004 (N=347)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 2.0 0.3 [0.0–1.6] 0.3 9.2 44.4 29.7 14.1 2.0 0.3
Lincosamides Clindamycin 0.3 2.0 [0.8–4.1] 0.6 2.0 23.3 48.7 18.2 3.2 1.7 0.3 0.3 1.2 0.6
Azithromycin 1.4 0.6 [0.1–2.1] 5.5 39.8 44.7 6.1 1.4 0.6 1.4 0.3 0.3
Erythromycin 0.6 0.3 [0.0–1.6] 0.6 0.9 10.4 48.4 27.7 9.2 1.7 0.3 0.6 0.3
Phenicols Chloramphenicol 2.9 1.4 [0.5–3.3] 0.6 2.3 42.9 35.7 10.7 3.5 2.9 1.4
Ciprofloxacin 0.0 19.0 [15.0–23.6] 0.6 36.3 36.0 6.6 1.2 0.3 0.3 1.4 17.3
Nalidixic Acid 0.6 19.6 [15.6–24.2] 0.6 11.0 38.0 21.3 6.9 2.0 0.6 0.3 19.3
Tetracyclines Tetracycline 0.3 46.1 [40.8–51.5] 2.0 20.7 22.8 6.1 1.2 0.6 0.3 0.3 1.4 4.6 5.8 5.8 1.2 27.4
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate 
breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. Numbers listed for the lowest 
tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.







Year 1997 1998 1999 2000 2001 2002 2003 2004




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.3%
(MIC ≥ 8) Tested 1 0 1 0 0 1 1
Lincosamides Clindamycin 1.8% 1.3% 1.3% 0.9% 2.1% 2.0% 0.6% 2.0%
(MIC ≥ 8) 4 4 4 3 8 7 2 7
Macrolides Azithromycin Not 0.6% 2.2% 1.9% 2.1% 2.0% 0.9% 0.6%
(MIC ≥ 8) Tested 2 7 6 8 7 3 2
Erythromycin 1.8% 1.0% 1.9% 1.2% 2.1% 1.4% 0.9% 0.3%
(MIC ≥ 32) 4 3 6 4 8 5 3 1
Phenicols Chloramphenicol 5.1% 2.9% 0.6% 0.0% 0.3% 0.3% 0.0% 1.4%
(MIC ≥ 32) 11 9 2 0 1 1 0 5
Quinolones Ciprofloxacin 12.9% 13.9% 18.3% 14.8% 19.5% 20.1% 17.7% 19.0%
(MIC ≥ 4) 28 43 58 48 75 71 58 66
Nalidixic acid 14.3% 16.8% 21.1% 16.7% 20.3% 20.6% 18.9% 19.6%
(MIC ≥ 64) 31 52 67 54 78 73 62 68
Tetracyclines Tetracycline 47.9% 45.5% 43.8% 38.3% 40.9% 41.2% 38.4% 46.1%
(MIC ≥ 16) 104 141 139 124 157 146 126 160
Table 5.3: Percentage and number of Campylobacter isolates resistant to antimicrobial agents, 1997–2004
 
 
Year 1997 1998 1999 2000 2001 2002 2003 2004
Total Isolates 217 310 317 324 384 354 328 347
% % % % % % % %
n n n n n n n n
No resistance detected 47.0% 45.2% 47.3% 52.2% 49.2% 48.3% 50.9% 46.1%
 102 140 150 169 189 171 167 160
Resistance ≥1CLSI subclass* 53.0% 54.8% 52.7% 47.8% 50.8% 51.7% 49.1% 53.9%
 115 170 167 155 195 183 161 187
Resistance ≥2 CLSI subclasses* 15.7% 9.7% 13.6% 8.0% 13.3% 12.7% 8.5% 14.1%
 34 30 43 26 51 45 28 49
Resistance ≥3 CLSI subclasses* 1.8% 2.6% 1.6% 0.9% 1.6% 1.1% 0.9% 1.2%
 4 8 5 3 6 4 3 4
Resistance ≥4 CLSI subclasses* 0.5% 0.3% 0.9% 0.3% 0.3% 0.0% 0.3% 0.3%
 1 1 3 1 1 0 1 1
Resistance ≥5 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 






Table 5.5: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to antimicrobial agents, 2004 (N=320)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 1.9 0.3 [0.0–1.7] 0.3 9.4 45.3 28.8 14.1 1.9 0.3
Lincosamides Clindamycin 0.3 2.2 [0.9–4.5] 0.6 2.2 25.3 48.1 18.1 2.2 0.9 0.3 0.3 1.3 0.6
Azithromycin 1.6 0.6 [0.1–2.2] 5.9 40.3 44.4 5.3 1.6 0.3 1.6 0.3 0.3
Erythromycin 0.3 0.3 [0.0–1.7] 0.6 0.9 10.0 49.7 28.4 7.8 1.6 0.3 0.3 0.3
Phenicols Chloramphenicol 3.1 1.6 [0.5–3.6] 0.6 2.5 45.9 35.3 8.4 2.5 3.1 1.6
Ciprofloxacin 0.0 18.1 [14.1–22.8] 0.6 36.9 37.8 5.6 0.9 1.6 16.6
Nalidixic Acid 0.6 18.4 [14.3–23.1] 0.6 11.9 39.4 20.6 6.9 1.6 0.6 0.3 18.1
Tetracyclines Tetracycline 0.3 46.9 [41.3–52.5] 2.2 22.2 21.3 5.3 1.3 0.3 0.3 0.3 1.6 4.7 5.6 5.6 1.3 28.1
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars 
indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. Numbers listed for 
the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when 
available.







Year 1997 1998 1999 2000 2001 2002 2003 2004




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3%
(MIC ≥ 8) Tested 1 0 0 0 0 0 1
Lincosamides Clindamycin 1.0% 1.0% 0.7% 0.7% 1.9% 1.8% 0.0% 2.2%
(MIC ≥ 8) 2 3 2 2 7 6 0 7
Macrolides Azithromycin Not 0.3% 1.7% 1.6% 1.9% 1.8% 0.3% 0.6%
(MIC ≥ 8) Tested 1 5 5 7 6 1 2
Erythromycin 1.4% 0.7% 1.4% 1.0% 1.9% 1.2% 0.3% 0.3%
(MIC ≥ 32) 3 2 4 3 7 4 1 1
Phenicols Chloramphenicol 3.8% 1.0% 0.7% 0.0% 0.3% 0.3% 0.0% 1.6%
(MIC ≥ 32) 8 3 2 0 1 1 0 5
Quinolones Ciprofloxacin 12.4% 13.8% 17.7% 14.7% 18.4% 20.7% 17.2% 18.1%
(MIC ≥ 4) 26 41 52 45 67 68 52 58
Nalidixic acid 13.4% 15.5% 20.1% 16.0% 18.9% 21.3% 17.8% 18.4%
(MIC ≥ 64) 28 46 59 49 69 70 54 59
Tetracyclines Tetracycline 47.8% 46.1% 45.4% 39.2% 40.3% 41.3% 38.3% 46.9%
(MIC ≥ 16) 100 137 133 120 147 136 116 150
Table 5.6: Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 1997–2004
 
 
Table 5.7: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to antimicrobial agents, 2004 
(N=26) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 3.8 0.0 [0.0–13.2] 7.7 30.8 42.3 15.4 3.8
Lincosamides Clindamycin 0.0 0.0 [0.0–13.2] 53.8 19.2 15.4 11.5
Azithromycin 0.0 0.0 [0.0–13.2] 34.6 46.2 15.4 3.8
Erythromycin 3.8 0.0 [0.0–13.2] 15.4 34.6 15.4 26.9 3.8 3.8
Phenicols Chloramphenicol 0.0 0.0 [0.0–13.2] 7.7 38.5 38.5 15.4
Ciprofloxacin 0.0 30.8 [14.3–51.8] 26.9 15.4 19.2 3.8 3.8 3.8 26.9
Nalidixic Acid 0.0 34.6 [17.2–55.7] 19.2 30.8 7.7 7.7 34.6
Tetracyclines Tetracycline 0.0 38.5 [20.2–59.4] 42.3 15.4 3.8 3.8 7.7 7.7 19.2
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
% of isolates Percent of all isolates with MIC (µg/mL)§
Macrolides
Quinolones
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical 
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints 




Year 1997 1998 1999 2000 2001 2002 2003 2004




Aminoglycosides Gentamicin Not 0.0% 0.0% 8.3% 0.0% 0.0% 4.5% 0.0%
(MIC ≥ 8) Tested 0 0 1 0 0 1 0
Lincosamides Clindamycin 16.7% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0%
(MIC ≥ 8) 1 1 2 1 1 1 2 0
Macrolides Azithromycin Not 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0%
(MIC ≥ 8) Tested 1 2 1 1 1 2 0
Erythromycin 0.0% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0%
(MIC ≥ 32) 0 1 2 1 1 1 2 0
Phenicols Chloramphenicol 50.0% 37.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) 3 3 0 0 0 0 0 0
Quinolones Ciprofloxacin 33.3% 0.0% 30.0% 25.0% 47.1% 12.0% 22.7% 30.8%
(MIC ≥ 4) 2 0 6 3 8 3 5 8
Nalidixic acid 50.0% 50.0% 30.0% 25.0% 47.1% 12.0% 22.7% 34.6%
(MIC ≥ 64) 3 4 6 3 8 3 5 9
Tetracyclines Tetracycline 66.7% 50.0% 30.0% 25.0% 58.8% 40.0% 45.5% 38.5%
(MIC ≥ 16) 4 4 6 3 10 10 10 10




Limitations to NARMS Campylobacter Surveillance 
 
Three limitations are evident in NARMS Campylobacter surveillance; the use of sentinel clinical laboratories in 
some states, the sampling scheme, and the limited geographic area under surveillance. In four states that 
participated in NARMS Campylobacter surveillance during 2004 (California, Colorado, Connecticut, and Oregon), 
Campylobacter isolates were submitted to NARMS from one sentinel clinical laboratory. In Georgia, Maryland, 
Minnesota, New Mexico, New York, and Tennessee, the Campylobacter isolates submitted were selected from all 
Campylobacter isolates from most clinical laboratories within a specific geographic area (metro Atlanta area in 
Georgia; statewide in Maryland, Minnesota, New Mexico, and Tennessee; and the metro Albany and Rochester 
areas in New York). In California, Colorado, Connecticut, and Oregon, the sentinel clinical laboratory selected the 
first Campylobacter isolate isolated each week for submission to NARMS; if no isolate was isolated in a week, 
then no isolate was submitted from that laboratory. Because none of the sentinel clinical laboratories used an 
isolation procedure that was more or less likely than the procedure of other clinical laboratories in their respective 
states to yield antimicrobial-resistant Campylobacter isolates, use of a sentinel clinical laboratory is unlikely to be 
associated with a change of antimicrobial resistance among Campylobacter isolates submitted to NARMS. 
 
In 2004, the NARMS participating public health laboratories in Georgia, Maryland, Minnesota, New Mexico, New 
York, and Tennessee, and sentinel clinical laboratories in all other FoodNet sites, selected one Campylobacter 
isolate each week and forwarded the isolate to CDC. When the isolates were selected, the antimicrobial resistance 
pattern of the isolates was not known. Therefore, the antimicrobial resistance pattern of an isolate is unlikely to 
influence submission of the isolate to NARMS. However, the one-a-week sampling scheme could result in 
oversampling or undersampling of antimicrobial-resistant isolates if the prevalence of such resistance is not uniform 
throughout the year. The impact of oversampling or undersampling can vary among states. 
 
Campylobacter isolates were forwarded to CDC by 10 states participating in FoodNet during 2004, representing 
approximately 45 million persons (15% of the U.S. population). Because NARMS 2004 Campylobacter surveillance 
was not nationwide, generalization of findings to the U.S. population should be done with caution because of 
possible regional differences in the prevalence of antimicrobial resistance among Campylobacter. 
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6. SUMMARY OF LONG-TERM CHANGES 
 
Non-Typhi Salmonella, 1979–2004 
 
For non-Typhi Salmonella, sentinel counties were surveyed during 1979–80, 1984–85, 1989–90, and 1994–95.8-11 
CDC tested isolates by disk diffusion. NARMS began testing Salmonella in 1996 with 14 participating sites, and 
by 2003 had expanded nationwide. From 1996 to 2002, participating sites forwarded every 10th non-Typhi 
Salmonella received at their public health laboratories to CDC. Since 2003, sites have forwarded every 20th 
isolate. In 2004, isolates were tested by broth microdilution to determine minimal inhibitory concentrations (MICs) 
to 15 antimicrobial agents. 
 
 
   
 
During the last quarter-century, resistance among non-Typhi Salmonella has increased to a number of clinically 
important antimicrobial agents (Figures 6.1 and 6.2). Resistance to ampicillin and trimethoprim-sulfamethoxazole 
increased first, reaching 20.7% and 3.9%, respectively, in 1996. Resistance to third-generation cephalosporins 
(e.g., ceftriaxone) and quinolones (e.g., nalidixic acid) and ACSSuT increased more recently. 
 
A public health concern raised by this resistance is loss of efficacious agents to treat serious Salmonella 
infections, especially in children. The clinical implications of current resistance levels are potential treatment 
failure, increased duration of illness, and increased length of hospitalization.10,12,13 For more information about 









Campylobacter jejuni, 1989–2004 
 
For Campylobacter jejuni, sentinel counties were surveyed during 1989–90.15 Isolates were received and tested 
at CDC. NARMS began testing Campylobacter in 1997 with five participating sites in 1997, seven in 1998, eight in 
1999, nine in 2000–2002, and 10 in 2003–2004. In 2004, one Campylobacter isolate per week was forwarded to 
CDC and tested by E-test to determine MICs to eight antimicrobial agents. 
 
During the last 16 years, C. jejuni resistance to a number of clinically important antimicrobial agents has changed 
(Figures 6.3 and 6.4). Resistance to tetracycline was already 42% in 1989–90 and has declined in more recent 
years. Resistance to ciprofloxacin has increased. No isolates resistant to ciprofloxacin were identified in 1989–90; 
12.4% were resistant in 1997, 20.7% in 2002, 17.2% in 2003, and 18.1% in 2004. Using the new CLSI interpretive 
criteria for macrolides, resistance to erythromycin remained low, at less than 2% from 1997 to 2004. Because 
poultry is the primary reservoir for C. jejuni, this increasing ciprofloxacin resistance is likely to be related to use of 
fluoroquinolones, which in 1995 were approved for use in poultry farming. This resistance raised public health 
concern because of the threat it posed to the efficacy of fluoroquinolones for treating campylobacteriosis. The 
clinical implications of resistance to fluoroquinolones include increased duration of illness and potential treatment 
failure.16 For more information about treatment of Campylobacter, see Diagnosis and Management of Foodborne 
















  Ampicillin Trimethoprim/Sulfamethoxazole         Third-generation cephalosporins              Nalidixic Acid               ACSSuT*  
   
* CSSuT = resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline 















          Figure 6.1: Sentinel county studies: 1979–1980, 1984–1985,      Figure 6.2: NARMS: 1996–2004 













































































     Tetracycline                Ciprofloxacin            Erythromycin   
Shigella, 1985–2004 
 
For Shigella, sentinel counties were surveyed during 1985–86 and 1995–96.17,18 Isolates were received and 
tested at CDC.  Since NARMS began testing Shigella in 1999, every 10th Shigella isolate received at participating 
state public health laboratories was forwarded to CDC during 1999–2002 and every 20th isolate during 2003–
2004. In 2004, isolates were tested by broth microdilution to determine MICs to 15 antimicrobial agents. 
 
During the last 19 years, resistance among Shigella isolates has increased to a number of clinically important 
antimicrobial agents (Figures 6.5 and 6.6). Resistance to ampicillin, already 32% in 1985–86, increased to 67% 
by 1995. Resistance to nalidixic acid emerged more recently. One Shigella isolate resistant to nalidixic acid was 
identified during 1985–86. The percentage of Shigella isolates resistant to nalidixic acid increased to nearly 2% in 
1999 but has remained at 2% or less. One isolate was resistant to ciprofloxacin in 2001. One ceftriaxone-resistant 
isolate was noted in 2004. 
 
Because Shigella has no environmental or animal reservoir except humans, this resistance probably is related to 
the use of antimicrobials in human medicine. A public health concern raised by these resistances is the loss of 
efficacious agents to treat Shigella infections. The clinical implication of current resistance levels is potential 
treatment failure. This may be particularly important for infections related to international travel.17,19 For more 
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7. SUMMARY OF ENTEROCOCCI RESISTANCE SURVEILLANCE, 2004 
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Enterococci are gram-positive cocci whose major habitat is the gastrointestinal tract of humans and other animals. 
Intestinal carriage of resistant enterococci in humans is associated with hospitalization and antimicrobial 
use. However, carriage of enterococci resistant to certain antimicrobial agents has been documented among 
persons who have not been hospitalized or recently taken antimicrobial agents, suggesting a community source. 
Antimicrobial agents commonly are used for growth promotion, disease prevention, and therapy in food animals, 
such as chickens and pigs. Such use results in the selection of resistant enterococci in the intestinal tracts of 
animals, suggesting that use of antimicrobial agents in food animals creates selective pressure on enterococci 
among food animals and ultimately might contribute to the pool of resistant enterococci among humans. 
Therefore, monitoring resistance in commensals is important to determine the role of these bacteria as reservoirs 
of resistance determinants for human pathogens. The Enterococci Resistance Surveillance project was designed 
to determine the prevalence of clinically important antimicrobial-resistant enterococci in stool samples among 
persons in the community. 
 
 




Enterococci resistance study began in 2001 to prospectively monitor the prevalence of antimicrobial resistance of 
human enterococci isolates from stool samples. The study includes five sites: Georgia, Maryland, Michigan, 
Minnesota, and Oregon. 
 
Multidrug-resistant enterococci 
• Multidrug resistance is described in NARMS by the number of antimicrobial subclasses or specific co-
resistance phenotypes. Antimicrobial subclasses are used as defined by CLSI. 
• 99.3% of Enterococcus faecium and 98.1% of Enterococcus faecalis isolates tested were resistant to two 
or more CLSI subclasses. 
• 17.8% of E. faecium and 30.2% of E. faecalis isolates tested were resistant to five or more CLSI 
subclasses. 
 
Clinically Important Resistance 
 
The number of antimicrobial agents available to treat serious enterococcal infections in humans is limited, in part 
because of the intrinsic resistance of enterococci to many antimicrobials and the ease with which the bacteria 
acquire resistance. Concern exists that currently available antimicrobial agents also progressively are losing 
effectiveness because of resistance, complicating treatment or presenting with serious enterococci infection. In 
particular, resistance has developed to gentamicin, penicillin, quinupristin-dalfopristin (Synercid®), and 
vancomycin. 
• 1.5% of E. faecium isolates and 6.2% of E. faecalis isolates were resistant to gentamicin. 
• 5.9% of E. faecium isolates and 1.2% of E. faecalis isolates were resistant to penicillin. 
• 3.7% of E. faecium isolates were resistant to quinupristin-dalfopristin. E. faecalis was not reported 
because of intrinsic resistance. 
• 0.7% of E. faecium isolates were resistant to vancomycin. No E. faecalis isolates were resistant to 
vancomycin. 
 
SURVEILLANCE AND LABORATORY TESTING METHODS 
 
Stool samples from outpatients with diarrhea and healthy volunteers were collected by laboratories in Georgia, 
Maryland, Michigan, Minnesota, and Oregon. All presumptive enterococci were submitted to the NARMS lab for 
species identification and antimicrobial susceptibility testing. Ten stool samples per month were requested. 
 
Predominant Enterococci  
 
Predominant enterococci were selected by mixing 0.5 grams of each stool in 5 mL of bile-esculin azide broth and 
incubating at 35–37°C for 48 hours. After incubation, 10 μL from a black culture was streaked onto Columbia 
CNA20 with 5% sheep blood and incubated at 35–37°C for 24 hours. A predominant colony with typical 
enterococci morphology were Gram stained and L-pyrrolidonyl-β-naphthylamide (PYR) spot-tested. 
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Enrichment for Vancomycin-Resistant Enterococci 
 
Vancomycin-resistant enterococci (VRE) were selected as above with the addition of 10 μg/mL vancomycin and 
10 μg/mL aztreonam to the bile-esculin azide broth. After incubation, 10 μl from a black culture was streaked onto 
Modified Ford agar21 supplemented with 10 g/mL raffinose and incubated at 35–37 C for 24 hours. A red colony 
characteristic of E. faecium and E. faecalis (raffinose nonfermenters) were Gram stained and PYR spot-tested. 
 
Enterococcus Species Identification and Antimicrobial Susceptibility Testing 
 
On arrival at CDC, isolates were subcultured on trypticase soy agar at least two times to obtain isolated single 
colonies. All incubations were performed at 35° ± 1°C. A pure culture was selected for definitive identification, 
antimicrobial susceptibility testing, and freezing at –70°C for archival purposes. Enterococci were identified to the 
species level according to standard biochemical methods.22 Antimicrobial susceptibility was tested by microbroth 
dilution using a custom Sensititre® panel, according to the manufacturer’s instructions (Trek Diagnostics, 
Cleveland, OH). MICs of antimicrobials were read manually using the Sensititre® Sensitouch™ system in 2001. In 
2002 and 2003, susceptibility results were read and interpreted using an automated system, ARIS™ by Trek 
Diagnostics. Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, E. faecalis ATCC 29212, and E. 
faecalis ATCC 51299 were used as quality controls for Enterococcus susceptibility testing according to CLSI 
guidelines.1 MICs were determined for 17 antimicrobial agents: bacitracin, chloramphenicol, ciprofloxacin, 
daptomycin, erythromycin, flavomycin, gentamicin, kanamycin, lincomycin, linezolid, nitrofurantoin, penicillin, 
streptomycin, quinupristin/dalfopristin, tetracycline, tylosin, and vancomycin (Table 7.1). 
 
Where established, CLSI interpretive criteria were used (Table 7.1). The 95% CIs for the percentage of resistant 
isolates calculated using the Clopper-Pearson exact method are included in the MIC distribution tables.6 Similarly, 







In 2004, CDC received 479 enterococci isolates, of which 474 (98.9%) were viable and tested for antimicrobial 
susceptibility (Table 7.2). Of the enterococci isolates tested, 54.4% (258/474) were E. faecalis, and 28.5% 
(135/474) were E. faecium (Table 7.3). 
 
MICs for E. faecium, E. faecalis, and other enterococci species were determined for each of the 17 antimicrobial 




Of the E. faecium isolates, 1.5% were resistant to gentamicin in 2004. Resistance to penicillin was 5.9% (Table 
7.5), and resistance to quinupristin/dalfopristin was 3.7%. Vancomycin resistance among E. faecium isolates was 




Of the E. faecalis isolates, 6.2% were resistant to gentamicin. Resistance to penicillin was 1.2% and 58.1% to 
tetracycline (Table 7.5). 
 
In 2004, 99.3% of E. faecium isolates were resistant to two or more CLSI subclasses, and 17.8% were resistant to 
five or more CLSI subclasses (Table 7.6). E. faecalis isolates resistant to two or more CLSI subclasses was 
98.1%, and resistance to five or more CLSI subclasses was 30.2% (Table 7.6). 
 
Enrichment for Vancomycin-Resistant Enterococci (VRE) 
 
In 2004, specimens from 13 patients yielded enterococci growth on VRE media. CDC received these isolates and 
tested them for antimicrobial susceptibility. Two isolates were confirmed E. faecalis, and neither were confirmed 
resistant to vancomycin. Five isolates were confirmed E. faecium, of which four were confirmed resistant to 
vancomycin. 
Resistant Intermediate Susceptible
Aminoglycoside Gentamicin 128 - 1024 ≥500      ≤256 CLSI
 Kanamycin 128 - 1024 ≥2048     ≤1024 DanMap
 Streptomycin 512 - 2048 ≥1000       ≤512 CLSI
Glycopeptide Vancomycin 0.5 - 32 32 8-16 ≤4 CLSI
Lincosamides Lincomycin 1 - 32 ≥8       ≤4 CASFM
Lipopeptides Daptomycin 0.5 - 16 ≥8       ≤4 CLSI
Macrolide Erythromycin 0.5 - 8 ≥8       1-4 ≤0.5 CLSI
 Tylosin 0.25 - 32 ≥8           ≤4 DanMap
Nitrofuran Nitrofurantoin 2 - 64 ≥128        64 ≤32 CLSI
Oxazolidinones Linezolid 0.5 - 8 ≥8       4 ≤2 CLSI
Penicillin Penicillin 0.5 - 16 ≥16      ≤8 CLSI
Phenicol Chloramphenicol 2 - 32 ≥32      16 ≤8 CLSI
Phosphoglycolipid Flavomycin 1 - 32 ≥16      ≤8 DanMap
Polypeptide Bacitracin 8 - 128 ≥64      ≤32 NORM-VET
Quinolone Ciprofloxacin 0.12 - 4 ≥4       2 ≤1 CLSI
Streptogramin Synercid QD 1 - 32 ≥4       2 ≤1 CLSI
Tetracycline Tetracycline 4 - 32 ≥16           8 ≤4 CLSI
Table 7.1: Antimicrobial agents used for susceptibility testing of Enterococci, NARMS, 2004














Table 7.2: Frequency of 





Enterococcus faecalis 258 (54.4%)
Enterococcus faecium 135 (28.5%)
Enterococcus avium 31 (6.5%)
Enterococcus durans 14 (3.0%)
Enterococcus casseliflavus 9 (1.9%)
Enterococcus hirae 8 (1.7%)
Enterococcus raffinosus 6 (1.3%)
Enterococcus gallinarum 5 (1.1%)
Enterococcus spp. 4 (0.8%)
Enterococcus pseudoavium 3 (0.6%)
Enterococcus sanguinicola 1 (0.2%)
Total 474 (100.0%)
Species 2004
Table 7.3: Enterococci speciation for isolates 












Table 7.4: Minimum inhibitory concentrations (MICs) and resistance of Enterrococcus isolates to antimicrobial agents, 2004 (N=474)
%I† %R‡ [95% CI]§ 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 4096
ENTFM NA 1.5 [0.2–5.3] 96.3 2.2 0.7 0.7
ENTFS NA 6.2 [3.6–9.9] 92.2 1.6 1.6 0.4 4.3
OTHER NA 1.2 [0.0–6.8] 98.8 1.2
ENTFM NA 2.2 [0.5–6.4] 73.3 22.2 2.2 2.2
ENTFS NA 17.8 [13.4–23.1] 79.8 2.3 17.8
OTHER NA 2.5 [0.3–8.7] 96.3 1.2 2.5
ENTFM NA 0.7 [0.0–4.1] 99.3 0.7
ENTFS NA 11.7 [8.0–16.2] 88.3 3.1 4.3 4.3
OTHER NA 11.1 [5.3–20.3] 88.9 1.2 8.6 1.2
ENTFM 0.0 0.7 [0.0–4.1] 80.0 14.8 4.4 0.7
ENTFS 0.0 0.0 [0.0–1.4] 0.4 54.7 39.5 5.4
OTHER 3.7 0.0 [0.0–4.5] 65.4 17.3 13.6 2.5 1.2
ENTFM NA 73.3 [64.8–80.4] 18.5 2.2 5.9 20.0 38.5 8.1 6.7
ENTFS NA 98.1 [95.5–99.4] 1.9 4.3 44.2 26.4 23.3
OTHER NA 82.7 [72.4–90.1] 7.4 9.9 48.1 28.4 6.2
ENTFM 0.0 8.9 [4.7–15.1] 5.9 5.2 21.5 58.5 8.9
ENTFS 0.0 0.0 [0.0–1.4] 24.8 67.8 7.4
OTHER 0.0 1.2 [0.0–6.8] 40.7 34.6 11.1 12.3 1.2
ENTFM 66.7 12.6 [7.6–19.5] 20.7 18.5 22.2 25.9 8.9 3.7
ENTFS 41.1 25.2 [20.0–31.0] 33.7 34.5 5.0 1.6 2.7 22.5
OTHER 25.9 18.5 [9.9–27.6] 55.6 17.3 2.5 6.2 3.7 14.8
ENTFM NA 37.8 [29.1–46.1] 0.7 9.6 19.3 32.6 27.4 7.4 0.7 2.2
ENTFS NA 25.6 [20.4–31.4] 19.8 50.8 3.9 0.4 0.8 24.4
OTHER NA 9.9 [4.4–18.8] 1.2 3.7 23.5 40.7 21.0 1.2 8.6
ENTFM 76.3 3.0 [0.5–6.4] 0.7 4.4 15.6 76.3 3.0
ENTFS 0.0 0.0 [0.0–1.4] 1.9 59.7 35.7 2.7
OTHER 40.7 14.8 [8.0–24.7] 4.9 9.9 8.6 21.0 40.7 14.8
ENTFM 3.0 0.7 [0.0–2.7] 2.2 49.6 44.4 3.0 0.7
ENTFS 2.3 0.4 [0.0–2.1] 1.9 77.1 18.2 2.3 0.4
OTHER 2.5 1.2 [0.0–6.8] 18.5 27.2 50.6 2.5 1.2
ENTFM NA 5.9 [2.1–10.5] 9.6 10.4 28.1 33.3 12.6 0.7 5.2
ENTFS NA 1.2 [0.2–3.4] 0.4 24.8 54.3 19.4 1.2
OTHER NA 3.7 [0.8–10.6] 27.2 17.3 40.7 11.1 1.2 2.5
ENTFM 1.5 1.5 [0.2–5.3] 1.5 71.9 23.7 1.5 1.5
ENTFS 0.8 6.6 [3.9–10.3] 0.8 52.3 39.5 0.8 3.9 2.7
OTHER 2.5 7.4 [2.8–15.6] 14.8 38.3 37.0 2.5 7.4
ENTFM NA 94.1 [88.6–97.4] 1.5 1.5 3.0 3.0 4.4 86.7
ENTFS NA 6.2 [3.6–9.9] 5.0 86.8 1.2 0.8 1.6 0.4 4.3
OTHER NA 49.4 [38.6–61.4] 2.5 19.8 22.2 6.2 4.9 2.5 42.0
ENTFM NA 91.1 [84.9–95.3] 3.0 0.7 5.2 25.9 52.6 12.6
ENTFS NA 92.2 [88.3–95.2] 1.2 6.6 27.5 54.7 10.1
OTHER NA 84.0 [73.8–91.1] 4.9 6.2 4.9 29.6 46.9 7.4
ENTFM 18.5 20.0 [13.7–27.9] 14.1 47.4 18.5 13.3 6.7
ENTFS 16.3 5.0 [2.7–8.5] 11.6 67.1 16.3 5.0
OTHER 33.3 9.9 [4.4–18.8] 1.2 4.9 19.8 30.9 33.3 1.2 8.6
ENTFM 53.3 3.7 [1.2–8.5] 43.0 53.3 0.7 0.7 1.5 0.7
ENTFS** NA NA NA
OTHER 21.0 3.7 [0.8–10.6] 75.3 21.0 1.2 1.2 1.2
ENTFM 3.0 24.4 [17.6–32.8] 72.6 3.0 5.2 19.3
ENTFS 1.6 58.1 [51.9–64.2] 40.3 1.6 6.6 36.8 14.7
OTHER 3.7 46.9 [35.0–57.8] 49.4 3.7 6.2 23.5 17.3
*ENTFM: Enterococcus faecium (n=135), ENTFS: Enterococcus faecalis (n=258), OTHER: all other Enterococcus spp. (n=81)
†Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
‡Percent of isolates that were resistant
§95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
**Intrinsic resistance to Quinipristin-Dalfopristin
















¶The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate 
breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the 


















Year 2001 2002 2003 2004 2001 2002 2003 2004 2001 2002 2003 2004
234 172 165 135 315 219 247 258 61 57 58 81
Antibiotic
Subclass (Resistance breakpoint)
Aminoglycosides Gentamicin 1.7% 0.6% 0.0% 1.5% 5.7% 6.4% 2.0% 6.2% 1.6% 0.0% 0.0% 1.2%
(MIC >500) 4 1 0 2 18 14 5 16 1 0 0 1
Kanamycin 8.5% 9.3% 2.4% 2.2% 14.9% 14.2% 8.9% 17.8% 4.9% 8.8% 3.4% 2.5%
(MIC ≥2048) 20 16 4 3 47 31 22 46 3 5 2 2
Streptomycin 4.3% 7.0% 2.4% 0.7% 14.6% 10.0% 7.7% 11.6% 11.5% 8.8% 3.4% 11.1%
(MIC >1000) 10 12 4 1 46 22 19 30 7 5 2 9
Glycopeptides Vancomycin 1.7% 2.3% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥32) 4 4 0 1 0 0 0 0 0 0 0 0
Ionophore coccidiostat Salinomycin 0.0% 0.6% 0.0% Not 0.0% 0.0% 0.0% Not 0.0% 1.8% 0.0% Not
(MIC ≥16 ) 0 1 0 Tested 0 0 0 Tested 0 1 0 Teste
Lincosamides Lincomycin 75.6% 69.8% 73.9% 73.3% 95.6% 98.6% 98.4% 98.1% 78.7% 86.0% 74.1% 82.7%
(MIC ≥8) 177 120 122 99 301 216 243 253 48 49 43 67
Lipopeptides Daptomycin Not Not Not 8.9% Not Not Not 0.0% Not Not Not 1.2%
(MIC ≥8) Tested Tested Tested 12 Tested tested tested 0 Tested Tested Tested 1
Macrolides Erythromycin 7.3% 15.1% 10.3% 12.6% 24.4% 19.2% 22.7% 25.2% 21.3% 21.1% 10.3% 18.5%
(MIC ≥8) 17 26 17 17 77 42 56 65 13 12 6 15
Tylosin 23.5% 20.3% 6.7% 37.8% 23.8% 20.1% 22.7% 25.6% 13.1% 10.5% 6.9% 9.9%
(MIC ≥8) 55 35 11 51 75 44 56 66 8 6 4 8
Nitrofurans Nitrofurantoin 14.1% 2.9% 0.0% 3.0% 0.3% 0.5% 0.0% 0.0% 13.1% 0.0% 0.0% 14.8%
(MIC ≥128) 33 5 0 4 1 1 0 0 8 0 0 12
Oxazolidinones Linezolid 0.0% 0.0% 0.0% 0.7% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 1.2%
(MIC ≥8 ) 0 0 0 1 0 0 0 1 0 0 0 1
Penicillins Penicillin 4.3% 7.6% 10.3% 5.9% 0.0% 2.3% 0.4% 1.2% 4.9% 8.8% 8.6% 3.7%
(MIC ≥16) 10 13 17 8 0 5 1 3 3 5 5 3
Phenicols Chloramphenicol 1.7% 0.0% 0.0% 1.5% 6.0% 7.3% 2.0% 6.6% 1.6% 0.0% 0.0% 7.4%
(MIC ≥32) 4 0 0 2 19 16 5 17 1 0 0 6
Phosphoglycolipid Flavomycin 79.9% 90.1% 90.3% 94.1% 2.5% 0.5% 0.0% 6.2% 42.6% 35.1% 50.0% 49.4%
(MIC ≥16) 187 155 149 127 8 1 0 16 26 20 29 40
Polypeptide Bacitracin 92.3% 93.6% 92.7% 91.1% 84.4% 90.4% 96.0% 92.2% 83.6% 87.7% 89.7% 84.0%
(MIC ≥64) 216 161 153 123 266 198 237 238 51 50 52 68
Quinolones Ciprofloxacin 15.0% 12.2% 18.2% 20.0% 4.4% 4.6% 3.2% 5.0% 1.6% 0.0% 1.7% 9.9%
(MIC ≥4) 35 21 30 27 14 10 8 13 1 0 1 8
Streptogramins Quinupristin-Dalfopristin 20.9% 2.3% 3.6% 3.7% Not Not Not Not 8.2% 3.5% 3.4% 3.7%
(MIC ≥4) 49 4 6 5 Reported§ Reported§ Reported§ Reported§ 5 2 2 3
Virginiamycin 0.9% Not Not Not 11.1% Not Not Not 0.0% Not Not Not
(MIC ≥8) 2 Tested Tested Tested 35 Tested Tested Tested 0 Tested Tested Tested
Tetracyclines Tetracycline 21.4% 18.0% 15.2% 24.4% 56.8% 57.5% 55.1% 58.1% 42.6% 47.4% 22.4% 46.9%
(MIC ≥16) 50 31 25 33 179 126 136 150 26 27 13 38
*ENTFM = Enterococcus faecium
†ENTFS = Enterococcus faecalis
‡OTHER = Enterococcus  spp.
§Intrinsic resistance to quinupristin-dalfopristin









Year 2001 2002 2003 2004 2001 2002 2003 2004 2001 2002 2003 2004
Total Isolates 234 172 165 135 315 219 247 258 61 57 58 81
% % % % % % % % % % % %
n n n n n n n n n n n n
No resistance detected 0.9% 1.7% 0.0% 0.0% 0.3% 0.5% 0.0% 0.0% 1.6% 0.0% 1.7% 1.2%
 2 3 0 0 1 1 0 0 1 0 1 1
Resistance ≥1CLSI subclass§ 99.1% 98.3% 100.0% 100.0% 99.7% 99.5% 100.0% 100.0% 98.4% 100.0% 98.3% 98.8%
 232 169 165 135 314 218 247 258 60 57 57 80
Resistance ≥2 CLSI subclasses§ 97.4% 96.5% 97.0% 99.3% 95.6% 96.8% 97.6% 98.1% 96.7% 98.2% 89.7% 92.6%
 228 166 160 134 301 212 241 253 59 56 52 75
Resistance ≥3 CLSI subclasses§ 86.3% 80.2% 73.9% 83.7% 84.8% 84.5% 90.3% 90.7% 70.5% 61.4% 56.9% 74.1%
 202 138 122 113 267 185 223 234 43 35 33 60
Resistance ≥4 CLSI subclasses§ 47.4% 38.4% 30.9% 48.1% 56.8% 50.2% 54.7% 58.5% 32.8% 28.1% 13.8% 38.3%
 111 66 51 65 179 110 135 151 20 16 8 31
Resistance ≥5 CLSI subclasses§ 19.7% 11.6% 9.1% 17.8% 30.5% 21.5% 23.1% 30.2% 14.8% 12.3% 6.9% 16.0%
 46 20 15 24 96 47 57 78 9 7 4 13
*ENTFM = Enterococcus faecium
†ENTFS = Enterococcus faecalis
‡OTHER = Enterococcus  spp.
§CLSI: Clinical and Laboratory Standards Institute
ENTFM* ENTFS† OTHER‡

























Vancomycin-resistant enterococci (VRE), a major cause of nosocomial infection, were isolated first in Europe in 1986 and in 
the United States in 1987 [Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant 
Enterococcus faecalis. Antimicrob Agents Chemother 1989;33:1588–91]. Avoparcin, a glycopeptide related to vancomycin, 
was used for growth promotion of food animals in Europe during 1975–1997 [Casewell M, Friis C, Marco E, et al. The 
European ban on growth-promoting antibiotics and emerging consequences for human and animal health. Antimicrob Agents 
Chemother 2003;52:159–61]. The use of avoparcin in food animals resulted in a reservoir of VRE in food animals, and after 
transmission of VRE through the food supply, a reservoir of VRE in persons in the European community. In the United States, 
avoparcin was never approved for use in food animals, and confirmed reports of VRE in persons outside of a health-care 
setting are lacking. An aim of the NARMS Enterococci Resistance Surveillance is to investigate community-associated VRE in 
the United States. 
 
As part of ongoing surveillance, stool samples from outpatients with diarrhea and healthy volunteers were collected by 
laboratories in Georgia, Maryland, Michigan, Minnesota, and Oregon. Beginning in 2001, stool samples were tested for 
enterococci. If present, one enterococci isolated from each sample was susceptibility tested for vancomycin. 
 
VRE (MIC ≥32 mg/L) was screened by polymerase chain reaction (PCR) for vanA, vanB, vanC, and vanD [Clark NC, Cooksey 
RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob 
Agents Chemother 1993;37:2311–7]. VRE also was tested by PCR for a macrolide-resistance determinant ermB [Tait-Kamradt 
A, Clancy J, Cronan M, et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. 
Antimicrob Agents Chemother 1997;41:2251–5] and tetracycline resistance determinant tetM [Aarestrup FM, Agerso Y, 
Gerner-Smidt P, Madsen M, Jensen LB. Comparison of antimicrobial resistance phenotypes and resistance genes in 
Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagn 
Microbiol Infect Dis 2000;37:127–37]. 
 
Of 2483 stool specimens tested during 2001–2004, 2002 (80.6%) yielded enterococci. Of 2002 enterococci isolates tested for 
susceptibility, 26 (1.3%) of the isolates were VRE, of which 24 (92.3%) were resistant to penicillin; 18 (69.2%), to 
erythromycin; 15 (57.7%), to tetracycline; and 11 (42.3%), to high-level gentamicin. Of the 23 VRE that were available for 
further characterization, 22 were E. faecium with vancomycin MICs ≥256 mg/L harboring vanA, and one was E. faecalis with a 
vancomycin MIC of 64 mg/L with vanB. All erythromycin- and tetracycline-resistant isolates contained ermB and tetM,, 
respectively. 
 
Figure 7.1: Prevalence of co-resistant phenotypes 




Molecular Characterization of Vancomycin-resistant enterococci isolated from persons in 
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Escherichia coli is a gram-negative rod that is part of the intestinal flora of humans and other animals. Because 
antimicrobial resistance genes commonly reside in mobile genetic elements that can be transferred horizontally to 
other bacteria, antimicrobial-resistant bacteria of the intestinal flora, including E. coli, constitute an important 
reservoir of resistance genes for pathogenic bacteria of humans and other animals. Furthermore, when 
introduced into a normally sterile site, E. coli is an important cause of infections, including septicemia, urinary tract 
infections, and wound infections. The human intestinal tract is the predominant source of E. coli causing these 
infections. Antimicrobial resistance among E. coli causing such infections complicates treatment options. 
 
The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant 
bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant E. coli in the 
intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply.1,2,3 
Therefore, monitoring resistance in E. coli isolated from the intestinal flora of humans and animals is important to 
determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for 
human pathogens.4 The E. coli Resistance Surveillance Pilot is designed to determine the prevalence of 
resistance to clinically important antimicrobial agents among E. coli isolated from persons in the community. 
 




Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of E. coli 
isolated from human stool samples in two sites: Maryland and Michigan. 
 
Multidrug-Resistant E. coli 
 
• 24.8% of 218 E. coli isolates tested were resistant to two or more subclasses of antimicrobial agents. 
• 6.9% of 218 E. coli isolates tested were resistant to five or more subclasses of antimicrobial agents. 
 
Clinically Important Resistance 
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Antimicrobial agents commonly used to treat serious E. coli infections in humans include third-generation 
cephalosporins and fluoroquinolones. 
• 0.9% of 218 E. coli isolates were resistant to ceftiofur (Table A.3). 
• 9.3% of 218 E. coli isolates were resistant to ciprofloxacin (Table A.3). 
 
SURVEILLANCE AND LABORATORY TESTING METHODS 
 
Participating laboratories in Maryland and Michigan cultured 10 human stool samples each month for E. coli using 
Eosin Methylene Blue agar one E. coli isolate, if present, from each stool sample was sent to CDC for 
susceptibility testing to antimicrobial agents using broth microdilution (Sensititre®) to determine the minimum 
inhibitory concentration (MIC) for each of 15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfamethoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table A.1). The resistance 
breakpoint for amikacin, according to CLSI5 guidelines, is an MIC of 64 µg/mL. 
 
Interpretive criteria from the Clinical Laboratory and Standards Institute (CLSI) were used (Table A.1). The 95% 
CIs for the percentage of resistant isolates calculated using the Clopper-Pearson exact method, are included in 
the MIC distribution tables. Similarly, multiclass resistance by CLSI antimicrobial subclass was defined as 




In 2004, CDC received and tested 218 viable E. coli isolates (Table A.2). MICs were determined for E. coli 
isolates for 15 antimicrobial agents (Table A.3). 
 
Resistance also was determined to specific antimicrobial agents during 2004 (Table A.4). Of the E. coli isolates, 
30.1% were resistant to ampicillin; 23.1%, to sulfamethoxazole; 19.0%, to nalidixic acid; and 17.1% to tetracycline 
(Table A-4). 
 
In 2004, 24.8% of E. coli isolates were resistant to two or more CLSI subclasses, and 6.9% were resistant to five 
or more CLSI subclasses (Table A.5).  
 
There is an apparent difference in the level of resistance among E. coli isolates in this study compared with E. coli 
O157 isolates submitted to NARMS in 2004. Because of the different sampling methods employed in this study 
and NARMS, this observation requires further investigation. 
 
Resistant Intermediate Susceptible
Amikacin* 0.5 – 4* >64 32 <16
Gentamicin 0.25 – 16 >16 8 <4
Kanamycin 8 – 64 >64 32 <16
Streptomycin 32 – 64 >64  <32
Aminopenicillins Ampicillin 1 – 32 >32 16 <8
β-lactamase inhibitor combinations Amoxicillin–Clavulanic acid 1/0.5 – 32/16 >32/16 46/8 <8/4
Ceftiofur 0.12– 8 >8 4 <2
Ceftriaxone 0.25 – 64 >64 16-32 <8
Cephamycins Cefoxitin 0.5 – 16 >32 16 ≤8
Folate pathway inhibitors Trimethoprim–Sulfamethoxazole 0.12/2.4 – 4/76 >4/76 <2/38
Phenicols Chloramphenicol 2 – 32 >32 16 <8
Ciprofloxacin 0.015 – 4 >4 2 <1
Nalidixic acid 0.5 – 32 >32 <16
Sulfonamides Sulfisoxazole 16 – 512 >512 <256
Tetracyclines Tetracycline 4 – 16 >16 8 <4
Table A.1: Antimicrobial agents used for susceptibility testing of Escherichia coli , NARMS, 2004
Breakpoints
* The resistance breakpoint for amikacin, according to Clinical and Laboratory Standards Institute (CLSI) guidelines, is 64µg/mL.  For isolates 
that grew in all amikacin dilutions on the Sensititre panel (minimum inhibitory concentration [MIC] >4 µg/mL), E-Test (AB BIODISK, Solna, 
Sweden) was performed in order to determine amikacin MIC.  The amikacin E-Test strip range of dilutions is 0.016-256 µg/mL.














Table A.2: Frequency of 






Table A.3: Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli isolates to antimicrobial agents, 2004 (N=216)
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.5 [0.0–2.6] 0.9 37.5 54.6 5.6 0.9 0.5
Gentamicin 0.0 5.1 [2.2–8.3] 22.2 61.1 11.1 0.5 5.1
Kanamycin 0.0 2.8 [0.8–5.3] 94.4 2.8 0.5 2.3
Streptomycin NA 14.4 [9.6–19.2] 85.6 3.7 10.6
Aminopenicillins Ampicillin 0.0 30.1 [24.1–36.7] 6.5 38.9 20.4 4.2 1.4 28.7
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 2.3 3.7 [1.6–7.2] 3.7 17.6 45.8 26.9 2.3 3.2 0.5
Ceftiofur 0.0 0.9 [0.0–2.6] 10.2 69.0 17.6 2.3 0.9
Ceftriaxone 0.5 0.5 [0.0–2.6] 97.2 1.9 0.5 0.5
Cephamycins Cefoxitin 1.9 3.2 [1.3–6.6] 4.2 31.5 50.9 8.3 1.9 2.8 0.5
Folate pathway 
inhibitors
Trimethoprim-sulfamethoxazole NA 15.7 [11.2–21.3] 73.6 9.3 1.4 15.7
Phenicols Chloramphenicol 2.8 1.9 [0.5–4.7] 6.5 62.0 26.9 2.8 1.9
Ciprofloxacin 0.0 9.3 [5.7–13.9] 79.2 1.9 1.4 4.2 3.7 0.5 9.3
Nalidixic Acid NA 19.0 [14.0–24.9] 15.3 56.5 8.8 0.5 2.3 16.7
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 23.1 [17.7–29.4] 66.2 10.2 0.5 23.1
Tetracyclines Tetracycline 0.0 17.1 [12.4–22.8] 82.9 3.2 13.9
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations represent 
the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Quinolones
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides













(MIC ≥ 64) 1
Gentamicin 4.6%
(MIC ≥ 16) 10
Kanamycin 2.3%
(MIC ≥ 64) 5
Streptomycin 13.9%
(MIC ≥ 64) 30
Ampicillin 30.1%
(MIC ≥ 32) 65
Amoxicillin-clavulanic acid 3.7%
(MIC ≥ 32) 8
Cephalothin Not
(MIC ≥ 32) Tested
Ceftiofur 0.5%
(MIC ≥ 8) 1
Ceftriaxone 0.5%
(MIC ≥ 64) 1
Cefoxitin 3.2%
(MIC ≥ 32) 7
Trimethoprim-sulfamethoxazole 15.7%
(MIC ≥ 4) 34
Chloramphenicol 1.9%
(MIC ≥ 32) 4
Ciprofloxacin 9.3%
(MIC ≥ 4) 20
Nalidixic Acid 19.0%
(MIC ≥ 32) 41
Sulfamethoxazole/Sulfisoxazole 23.1%
(MIC ≥ 512) 50
Tetracycline 17.1%
(MIC ≥ 16) 37




















No resistance detected 55.6%
 120
Resistance ≥1CLSI subclass* 45.4%
 98
Resistance ≥2 CLSI subclasses* 25.0%
 54
Resistance ≥3 CLSI subclasses* 16.2%
 35
Resistance ≥4 CLSI subclasses* 9.7%
 21
Resistance ≥5 CLSI subclasses* 6.9%
 15
At least ACSSuT† 1.4%
 3
At least ACSuTm‡ 1.9%
 4
At least ACSSuTAuCf§ 0.0%
 0
At least AAuC¶ 0.0%
 0
At least A3C** 0.0%
 0
At least MDR-AmpC†† 0.0%
 0
Resistance to quinolone and cephalosporin (3rd generation) 0.5%
 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶AAuC: resistance to ampicillin, amoxicillin-clavulanic acid, ceftiofur  
**A3C: resistance to amikacin, ampicillin, amoxicillin-clavulanic acid
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)  
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LIST OF ABBREVIATIONS 
 
 
ACSSuT Resistance to at least ampicillin, chloramphenicol, streptomycin, 
sulfamethoxazole/sulfisoxazole, and tetracycline 
ACSSuTAuC  Resistance to at least ACSSuT , amoxicillin-clavulanic acid, and ceftiofur 
ACSuTm  Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole 
CDC   Centers for Disease Control and Prevention 
CI   Confidence interval 
CLSI   Clinical and Laboratory Standards Institute 
EIP   Emerging Infections Program 
ELC   Epidemiology and Laboratory Capacity 
EMB   Eosin methylene blue 
ENTFM   Enterococcus faecium 
ENTFS   Enterococcus faecalis 
ERS   Enterococci Resistance Surveillance 
FDA   Food and Drug Administration 
FoodNet  Foodborne Diseases Active Surveillance Network 
MDR-AmpC Resistance to at least ACSSuT, amoxicillin-clavulanic acid, and ceftiofur, and decreased 
susceptibility to ceftriaxone (MIC ≥ 2 µg/mL) 
MIC   Minimum inhibitory concentration 
NARMS National Antimicrobial Resistance Monitoring System for Enteric Bacteria 
OR  Odds ratio 
PCR  Polymerase chain reaction 
PHLIS  Public Health Laboratory Information System 
VRE   Vancomycin-resistant enterococci 
 
